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ABSTRACT 
 
Atherosclerosis is a multifactorial and polygenic disease. Origin and progression of 
atherosclerosis involve multiple biological systems. The extracellular matrix protein biglycan 
(BGN) is involved in the pathogenesis of atherosclerosis at different stages. BGN affects the 
constitution and stability of the fibrous cap of the atherosclerotic plaque, mediates binding of 
low-density lipoproteins to the artery wall and exerts proinflammatory actions. We analyzed 
the transcriptional regulation of the human BGN gene, also with respect to individual 
promoter allelic constellations. In transient transfection experiments of the BGN 5'-flanking 
region and 5'-UTR, we identified an 1025 bp portion with sufficient transcriptional activity in 
endothelial (EA.hy926) and monocytic (THP-1) cell lines. Screening of 1198 bp of the 
promoter region in 57 individuals with cardiovascular disease (CVD) led to the validation of 
three genetic variants: G-578A (rs11796997), G-151A (Brand, unpublished data) and G+94T 
(rs5945197). Subcloning and resequencing revealed three common MolHaps:  
BGN-MolHap1 [G-578-G-151-G+94], BGN-MolHap2 [G-578-A-151-T+94] and  
BGN-MolHap3 [A-578-G-151-G+94]. Introduction of either MolHap2 or MolHap3 in a 1025 bp 
construct resulted in a significant decrease (all P-values <0.05) of transcriptional activity in 
both EA.hy926 and THP-1 cell lines. To identify the positions of cis-regulatory elements in 
the 5'-flanking region, we generated serial deletion constructs. Stimulation of THP-1 cells 
with transforming growth factor-beta1 (TGF-β1) increased transcriptional activity of wild 
type BGN promoter fragments up to 3-fold (all P-values <0.01). To identify trans-acting 
transcription factors, we performed co-expression, chromatin immunoprecipitation (ChIP), 
and EMSA experiments. Transcription factor SP1 was shown to activate transcriptional 
activity of promoter fragments up to 4-fold compared to mock control (all P-values <0.001) 
and physical SP1 interaction was confirmed in ChIP experiments for alleles G-151 and G+94 
in EA.hy926 cells. EMSA experiments revealed binding of c-FOS to the 5'-UTR position 
G+94T. TGF-β1 stimulation of THP-1 nuclear extracts enhanced SP1 interaction with 
position G-578A. In THP-1 cells, ETS family member PU.1 bound the major allele G-578 
with higher affinity (4-fold) compared to the minor allele  
-578A. We conclude that BGN gene expression is under the control of activating transcription 
factor SP1. TGF-β1 reinforces SP1 binding and enhances transcriptional activity of the BGN 
promoter. The polymorphic position G+94T reside within a cis-active promoter element 
where AP-1 complex formation was observed. Monocyte-specific regulation of BGN 
expression is also controlled by ETS TF PU.1. 
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1 INTRODUCTION 
 
1.1 Cardiovascular Disease (CVD) 
 
CVD include hypertension, coronary heart disease (CHD), cerebrovascular disease, peripheral 
artery disease, rheumatic heart disease, congenital heart disease, and heart failure. Globally, 
CVD is the leading cause of death for women and men. In 2005 an estimated 17.5 million 
people died from CVD, representing 30% of all global events (WHO). Sixty-one percent of 
cardiovascular deaths occur due to specified risk factors, which include high blood pressure 
(~54% of deaths in European countries), high body mass index, high cholesterol, high blood 
glucose, unhealthy diet and physical inactivity. Above all, family history of CVD strongly and 
independently determines future CVD risk in individuals (Myers et al., 1990), underlining a 
major impact of genetic predisposition. 
 
1.2 Arteriosclerosis 
 
Arteriosclerosis represents the pathophysiological basis of CVD. The term literally refers to 
‘hardening of the arteries’, which resembles early reports on its observed pathophysiology. 
Terminology and classification of arteriopathic subcategories are still part of ongoing debates 
(Fishbein & Fishbein, 2009). Commonly accepted, arteriosclerosis is a systemic disease with 
particularly noticeable manifestations in the medium and large arteries and a strong 
inflammatory background. Atherosclerosis represents the most important form of 
arteriosclerosis, describing loss of elasticity of affected arteries due to atheromatous plaque 
formation (fig. 1). 
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Figure 1: Development of atherosclerotic lesions.  
The development of an atherosclerotic lesion is shown from left to right, from a normal blood vessel to 
a vessel with an atherosclerotic plaque and superimposed thrombus. Stages I to VI (below) are 
depicted according to the American Heart Association. The process representing specific stages of the 
lesion is shown at the top of the figure. (I) Lipoprotein particles, especially LDL, enter the arterial wall 
and undergo modification, including oxidation. The endothelial cells dysfunction is marked by 
inhibition of nitric oxide production. Oxidised LDL particles lead to endothelial cell activation with 
subsequent expression of adhesion molecules (ICAM-1, VCAM-1 and selectines) and inflammatory 
cytokines. (II) Monocytes are recruited into the subendothelial space, guided by chemokines. 
Differentiated into macrophages, they take up oxLDL and transform into lipid-laden foam cells. 
Infiltrating T-cells produce adhesion molecules, cytokines and chemokines leading to an ongoing 
immune activation. (III-IV) Apoptosis of foam cells leads to necrotic core formation. VSMC migrate 
into the developing plaque, forming a fibrous cap. (V-VI) Formation of stable or unstable plaques with 
potential rupture and thrombus formation. Figure adapted with permission from Z. Fayad (Sanz & 
Fayad, 2008). 
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1.2.1 Pathophysiology of atherosclerosis 
Atherosclerosis is a progressive, multifactorial, and proinflammatory disease characterized by 
the accumulation of lipids in distinct regions of the arterial wall designated as atherosclerotic 
plaques. Changes of the arterial wall due to atherosclerotic processes begin in early childhood 
and is a slow and silent process.  
Clinical manifestation with noticeable symptoms is not commonly detectable before 30 years 
of age, depending on individual predisposing factors. Despite other potential inducers of 
atherosclerosis pathophysiology, infiltration and retention of lipids from blood into the intima 
of the arterial wall is a pivotal process in disease development and progression (fig. 1). 
Elevated low-density lipoprotein (LDL) plasma levels result in binding of LDL to 
proteoglycans in the subendothelial matrix, where modification through oxidative and 
enzymatic (i.e. myeloperoxidase, lipoxygenases and others) processes takes place yielding 
oxLDL (Skålén et al., 2002). LDL thereby passively diffuses through endothelial cell 
junctions, with preference to regions of arterial branching or curvature, were no particular 
orientation of the cells in blood flow direction is observed. Activation of endothelial cells by 
phospholipids released from LDL may result in expression of several adhesion molecules 
such as VCAM-1, ICAM-1 and selectins on the endothelial surface (Steinberg, 2009). Upon 
interaction of adhesion molecules with carbohydrate ligands on the surface of blood 
monocytes, rolling, adhesion, and subsequently transmigrate of the monocyte into the 
subendothelial space takes place in response to different chemokines. Macrophage colony-
stimulating factor (M-CSF) induces proliferation and differentiation into macrophages (Yan 
& Hansson, 2007). This process is associated with upregulation of pattern-recognition 
receptors including scavenger receptors (Hofnagel et al., 2007) which mediate the uptake of 
oxLDL leading to foam cell formation and Toll-like receptors initiating inflammatory 
activation (Hansson, 2009). Native LDL is not taken up by macrophages very rapidly and 
LDL modification is crucial for early lesion formation. Anti-atherogenic processes are thereby 
interfered by oxLDL since it inhibits the production of nitric oxide, a strong mediator of 
vasorelaxation. This early stage in atherosclerosis pathophysiology, characterized by the 
subendothelial accumulation of lipid-laden macrophages, is termed the fatty streak. During 
the formation of the atherosclerotic plaque, the shoulder regions determine its future stability 
to a great extend. Here, T-cells of the lesion, with domination of CD4+ cells over CD8+ cells, 
are concentrated in clusters (Robertson & Hansson, 2006). On ongoing immune activation in 
these regions is marked by MHC class II-expressing macrophages and dendritic cells 
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(Jonasson et al., 1985). Infiltrating T-cells are activated by local antigens such as oxLDL 
components or heat shock protein 60/65 (Robertson & Hansson, 2006), resulting in the 
expression of various cytokines and differentiation into Th1 effector cells. The prototypic Th1 
cytokine interferon-γ (IFN-γ) promotes macrophage and endothelial activation with 
production of adhesion molecules, cytokines and chemokines and secondary increases the 
expression of tumor necrosis factor-α (TNF-α) and IL-1 (Hansson, 2001). Targeted deletion 
of IFN-γ or its receptor reduces disease progression, while recombinant IFN-γ accelerates 
lesion formation. The resulting local concentration of synergistic cytokines induce the 
proliferation and migration of VSMC, which in turn concentrate ECM components within the 
advanced atherosclerotic lesion. The advanced lesion is mainly composed of a necrotic core 
with accumulation of lipid-laden macrophages and extracellular lipid droplets derived from 
dispersed foam cells. A cap of VSMC and a collagen rich matrix is formed, characterizing the 
composition of the fibrous cap and its mechanical strength.  
Acute coronary events depend principally on the composition and vulnerability of the plaque 
and the status of a plaque from stable to unstable can change within a very short period of 
time under certain pathophysiological conditions. Underlying mechanisms are still under 
investigation, with a focus on endothelial (Hirschi et al., 2008) and smooth muscle (Sata et al., 
2002) progenitor cells trafficking in the vascular wall (for a review see Hristov & Weber, 
2008). Increasing numbers of inflammatory cells may contribute to unstable plaque formation 
by weakening of the plaque shoulder regions, making the cap more vulnerable to shear stress, 
leading incidentally to plaque rupture with subsequent thrombus formation by adhering 
platelets and fibrin crosslinks. Plaque erosion is another cause of acute coronary thrombosis. 
Eroded plaques are rich in SMC and proteoglycans, with relatively few inflammatory cells. 
The main cap proteoglycans, versican, BGN, and decorin (DCN), in combination with 
hyaluronan accumulate in topographically distinct patterns. Not only do these molecules 
contribute to plaque burden, but influence the biomechanical properties of vascular lesions 
and the ability of plaques to resist rupture. Stable plaques are thereby marked by increased 
accumulation of versican and BGN whereas plaque erosion is characterized by aggregation of 
hyaluronan and absence of BGN (Kolodgi et al., 2002) 
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1.3 BGN as a candidate for CVD pathophysiology 
 
BGN, or proteoglycan-I (PG-I), has been first described in 1983 by Fisher et al. (Fisher et al., 
1983). The human BGN represents a single copy gene and was mapped to the long arm of the 
X-chromosome (Xq28). BGN consists of eight exons, including exon one encoding the  
5’-untranslated region of the mRNA, seven introns and spans over 9.5 kbp of DNA. It is 
transcribed into nine transcripts by the alternative use of TSS and multiple splicing events. 
BGN is broadly expressed in the human body with high mRNA levels in lung, placenta, liver, 
retina and the heart. Altered BGN expression has been reported under several pathological 
conditions including cancer (Wong et al., 2009; Valladares et al., 2006), hypertension (Sardo 
et al., 2009) and atherosclerotic plaque formation (Riessen et al., 1994; Kolodgie et al., 2002; 
Adiguzel et al., 2009). BGN expression is influenced by a number of cytokines. TGF-β1 has 
been identified as a positive regulator of BGN expression (Lijnen et al. 2000; Ungefroren et 
al., 2003; Burch et al., 2010) and a negative feedback loop for BGN regulating TGF-β1 
activity has been suggested (Ruoslahti & Yamaguchi, 1991). TNF-α decreased BGN  
steady-state mRNA levels (-62%) and the BGN core protein gene transcription rate (-18%) in 
human chondrocytes (Dodge et al., 1998). The combination of IFN-γ and TNF-α resulted in a 
potentiation of the observed inhibitory effect. The important role of BGN in circulating 
monocytes has been emphasized repeatedly and a decrease in BGN expression has been 
reported after incubation with glucocorticoids (Kimoto et al., 1994). Treatment with 
angiotensin II has been shown to increase BGN mRNA expression in patients’ blood 
monocytes (Sardo et al., 2009). 
BGN is one of at least nine small leucine-rich proteoglycans (SLRP) which are secreted 
extracellular matrix components with different localization, expression and function. Grouped 
into three different classes (Iozzo, 1999), all of them can be described as either glycoproteins 
containing N-linked oligosaccharides or as proteoglycans containing chondroitin/dermatan 
sulfate or keratin sulfate chains (fig. 2). Class I comprises DCN and BGN which show a high 
homology (57%) and have been proposed to have evolved from an ancestral gene by gene 
duplication (Krusius et al., 1986). BGN and DCN are the only SLRP members that contain a 
highly conserved pro-peptide which might serve as a recognition signal for the 
xylosyltransferase. Both contain ten leucine-rich repeats (LRR) flanked by cystein-rich 
regions (Krishnan et al., 1999) and either one (DCN) or two (BGN) chondroitin/dermatan 
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sulfate chains at their N-terminal domain. Other members of the SLRP family are 
fibromodulin (FMOD), lumican (LUM), keratocan (KERA), PRELP and osteomodulin 
(OMD) in class II as well as epiphycan (DSPG3) and osteoglycin (OGN). 
 
 
 
 
 
Figure 2: Schematic representation of the BGN protein, indicating major domains.  
N-terminal: two glycosaminoglycan (GAG) chains (yellow), C: cystein residues, 10 leucine-rich 
repeats (LRR, blue). BGN self-aggregates into dimers and hexamers under physiological conditions. 
With modifications from Krishnan et al., 1999. 
 
 
The versatile role of BGN in pathophysiological processes has been extensively studied in 
animal models. Heegaard et al. (Heegaard et al., 2007) reported a vascular phenotype in  
BGN-knock out (ko) mice. BGN-deficiency caused aortic rapture across intima and media and 
dissection of the aortic wall. This observation was predominantly male-specific, since 50% of 
male ko mice died within three month of age but female mice showed similar phenotypes as 
wt. Corsi and colleagues (Corsi et al., 2002) highlighted the impact of BGN-deficiency on 
collagen fibrillogenesis. The group observed structural abnormalities in collagen fibril 
deposition in bone, dermis, and tendon of male BGN-ko mice. A very comprehensive study 
was presented by Westermann et al. (Westermann et al., 2008), investigating the role of BGN 
during cardiac ECM remodeling and cardiac hemodynamics after MI. They observed 
increased mortality, high frequency of cardiac ruptures, and aggravated cardiac failure in male 
ko animals after experimental MI due to perturbed collagen remodeling in the infarct scar 
tissue. In wt mice, BGN expression was strongly upregulated after MI, peaking in parallel to 
collagen content and was found in the infarct scar and border zones using 
c
c
c
c cc
NH2 OOH
LRR 
GAG 
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immunohistochemistry. The dual nature of BGN as a signalling molecule and a crucial 
proinflammatory factor was highlighted by Schaefer and colleagues (Schaefer et al., 2005). 
BGN-ko mice had a survival benefit compared with wt animals in induced sepsis due to 
decreased inflammatory response resulting in less organ damage. In addition, they provide 
evidence that macrophages are capable of producing BGN upon stimulation by 
lipopolysaccharide-induced proinflammatory factors. In a previous report the group observed 
concurrence of BGN overexpression and increased numbers of infiltrating cells in a model of 
renal inflammation (Schaefer et al., 2002). 
 
1.4 Polymorphic structure of the BGN gene 
 
In initial studies (Brand, unpublished data), the 5'-flanking region, exons, introns, and the 3'-
flanking region of the BGN gene were scanned for alterations in genomic DNA from 95 
patients of the ECTIM study. ECTIM (Etude Cas-Témoins de l'Infarctus du Myocarde) is a 
study of patients with MI (Cambien et al., 1992) from regions covered by the World Health 
Organization’s Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) 
registers and of control subjects (cases [n=988, mean±SD age 55.8±8.1 years, 26.2% women], 
controls [n=949, mean±SD age 56.6±8.3, 27.0% women]). 
 
 
Figure 3: Schematic representation of the BGN gene. 
The BGN gene consists of eight exons, shown in blank bars and seven introns. The single copy gene is 
located on the long arm of the X-chromosome at the proximal region Xq28. The untranslated exonic 
regions (5' and 3') are indicated by shaded bars. Identified SNPs with relative position are depicted 
below. Promoter SNPs are indicated in red. The major TSS is marked by an arrow (adopted from 
Brand, unpublished and Rüssmann, MD thesis).  
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Twelve SNPs were identified using SSCP analysis (fig. 3), five of which were located in 
intronic regions (G51A, G134A, G315T, G57T and G91T; designation according to end of 
upstream exon), two synonymous polymorphisms were found in exons two (Ser47Ser) and 
four (Ser206Ser). In the 5'-region, five SNPs were detected, one residing in the 5'-UTR of the 
gene. SNPs G-849A (rs56134709), G-578A (rs11796997) and G+94T (rs5945197) were 
already listed at NCBI (National Center for Biotechnology Information), SNP G-151A and  
C-501A had not been reported before. SNPs G-849A was detected one and C-501A twice 
within the 95 ECTIM DNA samples. 
In a further analysis (Rüssmann, MD thesis), three MolHaps have been suggested to be 
formed by variants G-578A, G-151A and G+94T, based on SSCP results only (sensitivity of 
variant detection by SSCP <80%; fig. 4).   
 
 
 
      
G  G  G 
 
     G  A  T 
 
     A  G  G 
 
 
Figure 4: Postulated MolHaps of the human BGN 5'-flanking region. 
Estimated frequencies among ~72% of analysed and evaluable DNA samples: BGN-MolHap1: ~19%, 
BGN-MolHap2: ~46% and BGN-MolHap3: ~36% (adopted from Rüssmann, MD thesis). 
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1.5 TGF-β1 cytokine signalling pathway 
 
TGF-β1 is a multifunctional peptide that controls proliferation, differentiation, and other 
functions in different cell types. TGF-β1 binds to membrane receptor serine/threonine kinases 
which form a bi-dimeric receptor complex (fig. 5), consisting of two pairs of subunits known 
as receptor type I (TGFBR1) and type II (TGFBR2). A membrane-anchored proteoglycan, 
designated type III receptor (TGFBR3), contributes to this process by capturing and 
presentation of TGF-β1 to the signalling receptors I and II. Upon TGF-β1 binding, TGFBR1 
phosphorylates receptor-bound SMAD2/3 TF, releasing them into the cytoplasm with 
subsequent translocation into the nucleus. As a common partner, SMAD4 serves as a 
mediator of transcriptional activation (for a comprehensive review see Massagué & Gomis, 
2006). Animal models provided evidence that TGF-β1 signalling pathway plays a pivotal role 
for ECM formation. In rats, administration of TGF-β1 neutralizing antibodies suppressed the 
expression of genes ECM components (Sharma et al., 1996). Transgenic mice overexpressing 
TGF-β1 predominantly in odontoblasts showed increase in dentin ECM components and 
abnormal deposition in the dental pulp (Thyagarajan et al., 2001). SMAD2, SMAD3, and 
SMAD4 are highly expressed in macrophage-derived foam cells of fatty streaks (Kalinina et 
al., 2004). SMC in these lesions do not express SMAD and TGF-β1 signalling is impaired 
with subsequent suppression of ECM components. In contrast, SMC in stable fibrous plaques 
express high levels of SMAD and ECM proteins. TGF-β1 is therefore a potential therapeutic 
target and it has recently been suggested to block TGF-β signal transduction and downstream 
proteoglycan synthesis in vascular SMC (VSMC) for the prevention of CVD using p38 MAP 
kinase inhibitors (Osman et al., 2008). This approach is problematic to some extend since 
plaque formation is an ongoing process with early onset in the development of atherosclerosis 
and TGF-β signal inhibition could support formation of unstable plaques. Selective local 
restoration of TGF-β responsiveness, leading to stabilization of atherosclerotic lesions is 
suggested to be a promising concept. On the other hand, findings of Suthanthiran et al. 
(Suthanthiran et al., 2000) indicate that TGF-β1 overexpression is a risk factor for 
hypertension and hypertensive complications. 
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Figure 5: The TGF-β1 signalling pathway.  
TGF-β1 binds to the receptor TGFBR2 upon capturing and presentation by TGFBR3 (dotted lines). 
TGFBR2 recruits and phosphorylates TGFBR1 with subsequent phosphorylation (P) of SMAD2 and 
SMAD3. This process is inhibited by SMAD7. Activated SMAD2/3 form heterodimers with SMAD4 
and translocate to the nucleus. Regulation of gene expression is coordinated by co-activators,  
co-repressors and other transcription factors. With modifications from Pinzani & Marra, 2001. 
 
1.6 Gene expression control 
 
As the Human Genome Project has been almost completed, the complexity of gene expression 
control has become exposed. Only 2–3% of the human genome encode for proteins, far less 
than originally apparent. The observed phenotype plasticity distinguishing the various types 
of cells throughout the human body are rather the result of differences in gene expression than 
a great variety of different coding genes. Orchestrated cellular proliferation and differentiation 
processes are controlled by a diversity of programs, regulating gene expression. These 
processes are crucial steps in maintenance of cellular homeostasis as well as in specific 
responses after signal transduction stimulation under pathophysiological conditions. Gene 
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expression can be regulated at different control levels. The most important being chromatin 
packaging, transcription, transcript processing, nuclear export, transcript stability, translation 
and protein stability/activity. Despite the diversity of potential levels of regulation, the 
majority of regulatory events are under transcriptional control (Villard, 2004). 
 
1.6.1 Transcriptional control 
Coding genes are under the control of at least one but more likely several, alternative 
promoters. High-resolution maps of active promoters in the human genome have suggested an 
average of about 3.1 promoters per gene (Kim et al., 2005; Cheong et al., 2006), underlining 
the complexity of transcriptional control. In general, one promoter is located within the  
5'-flanking region of a gene and alternative promoters can reside within intronic or exonic 
regions of the same or an adjacent gene. To date, the exact localization of promoter regions 
for most human genes is still unknown (Barrera & Ren, 2006). In eukaryotes transcription is 
controlled at different levels. Chromatin condensed by nucleosomal packaging is inaccessible 
for RNA Polymerase II (Pol II) and genes residing in packed regions are transcriptionally 
silent (Segal & Widom, 2009). Histone acetylation and gene methylation are the two main 
mechanisms involved in reactivation of silenced genes. Eukaryotic Pol II requires the 
assembly of the general transcription machinery at the promoter for initiation of gene 
transcription. In a next step, binding of regulatory trans-acting factors at cis-active elements 
occurs, which interact with the general transcription machinery. Co-regulatory factors 
(bridging-proteins such as p300), which do not bind DNA but interact with proteins of the 
general machinery and TF are involved in mediation of distal regulatory regions with the core 
promoter. After initiation of RNA synthesis, the transition to productive elongation is 
controlled as well. Pol II has been observed to stop after elongation of 20–50 nucleotides into 
the gene, designated as Pol II stalling within the proximal promoter regions (Muse et al., 
2007). This concept has been suggested for transcripts involved in rapid signal cascades, 
where Poly II is pre-engaged at the promoter without active transcription awaiting signals for 
transcript elongation (Buratowski, 2008). Activated genes display another characteristic 
feature, which is the ability to switch their conformation. Interaction of promoter elements 
and 3'-associated factors may initiate a loop structure, retaining Pol II once a full transcription 
cycle has completed with no need for reassembly of the transcription machinery (Moore & 
Proudfoot, 2009). In addition, a connection between promoter usage and alternative splicing 
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has been discussed, involving the recruitment of factors with dual functions in transcription 
and splicing, linking the two processes (Kornblihtt, 2005). Generated and stable mRNA 
transcripts are targets of naturally occurring knock-down events by RNA interference (RNAi) 
(Fire et al., 1998).  
 
1.6.2 The general transcription machinery 
The core promoter in eukaryotes serves as a platform for the assembly of the transcription 
preinitiation complex (PIC). Formation of the PIC is necessary since Pol II itself lacks 
sequence-specific recognition ability. For promoter function, proper assembly and formation 
of the PIC at characteristic DNA sequences is required. Seven eukaryotic core promoter 
elements have been identified so far (fig. 6; Thomas & Chiang, 2006), the most prominent 
being the TATA box, represented by an A/T-rich sequence located 25 to 30 nucleotides 
upstream of the TSS. PIC formation at this motive depends on recognition by the  
TATA-binding protein (TBP) or the TBP subunit of the TFIID complex. A TATA box (Smale 
& Kadonaga, 2003) is present in only <20% of human promoters (Kim et al., 2005) and other 
core promoter elements, either alone or in combinations are used. Data from functional 
studies suggest that human housekeeping genes, growth factors and transcription factors often 
lack a TATA element (Zhou & Chiang, 2001). In close vicinity of the TSS (-2 to +5 bp), the 
initiator (Inr) is located, which is recognized by the TAF1/TAF2 components of TFIID. It is 
capable of directing transcription initiation alone or in conjunction with the TATA box or 
other core promoter elements. The downstream promoter element (DPE) is often found in 
human TATA-less promoters and recognized by TAF6 and TAF9 dimeric complex (Shao et 
al., 2005). In addition to the DPE, two other downstream core promoter elements have been 
identified. The motif ten element (MTE) usually interacts with the Inr to enhance Pol II 
transcription but is capable of substituting the loss of a TATA box or DPE and can act 
synergistically with both elements in an Inr-dependent manner (Lim et al., 2004). In contrast 
to all other core promoter elements, the downstream core element (DCE) contains three 
discontinuous subelements (CTTC, CTGT, AGC), spanning +6 to +34 adjacent to the TSS 
(Lee et al., 2005b). Although originally identified in TATA box promoters, the two  
TFIIB-recognition elements (BRE) are found in many TATA-less promoters. The upstream 
BRE (BREu) is also capable of binding TFIIB independently of TBP, while downstream BRE 
(BREd) appears to be TBP-dependent (Deng & Roberts, 2005). The variability of these seven 
1 Introduction 
 
page | 13  
 
core promoter elements with their diverse consensus sequences and potential of multivalent 
combination underline the complexity of eukaryotic promoters. This complexity as well 
accounts for so far still inaccurate in silico prediction of core promoter elements, despite new 
approaches with improved accuracy (Zhang, 2007; Zeng et al., 2009).  
 
 
 
 
Core Promoter Element Position Consensus Sequence (5'-3') Bound Protein 
BREu -38 to -32 (G/C)(G/C)(G/A)CGCC TFIIB 
TATA -31 to -24 TATA(A/T)A(A/T)(A/G) TBP 
BREd -23 to -17 (G/A)T(T/G/A)(T/G)(G/T)(T/G)(T/G) TFIIB 
Inr -2 to +5 PyPyAN(T/A)PyPy TAF1/TAF2 
MTE +18 to +29 C(G/C)A(A/G)C(G/C)(G/C)AACG(G/C) n.a. 
DPE +28 to +34 (A/G)G(A/T)CGTG TAF6/TAF9 
DCE 
3 subelements 
+6 to +11 
+16 to +21 
+30 to +34 
core sequence: 
CTTC 
CTGT 
AGC 
TAF1 
 
Figure 6: Core promoter elements recognized by TFIIB or TFIID. 
TFIIB (green) and TFIID (yellow) recognize different core promoter elements. The TATA box is 
recognized by the TBP subunit of the TFIID complex. The table below lists the consensus sequences 
and respective positions for each core promoter element. n.a.: not available. With modifications from 
Thomas & Chiang, 2006. 
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1.6.2.1 Different pathways for PIC assembly 
Understanding the assembly pathways of transcription complexes at distinct core promoter 
regions is crucial for the understanding of the gene transcription mechanisms. Two pathways 
have so far been identified to lead to functional PIC assembly at the site of core promoter 
elements. Transcription factors required for Pol II-mediated transcription and identified 
accessory factors had been designated earlier by their presence in different isolated fractions 
of nuclear extracts TFIIA to TFIIH (Thomas & Chiang, 2006). 
 
1.6.2.2 The sequential assembly pathway 
This pathway has been identified after intensive study of in vitro transcription experiments, 
describing multiple essential steps and a hierarchical nature for the assembly of an initiation-
competent PIC. Buratowski et al. (Buratowski et al., 1989) specified the order of entry and 
relative position of each general transcription factor, which was refined in later experiments. 
Initially, TFIID recognizes the TATA box, followed by separate addition of TFIIA and TFIIB 
stabilizing promoter-bound TFIID, followed by recruitment of Pol II/TFIIF. This stable 
complex is completed by addition of accessory factors TFIIE and TFIIH.  
 
1.6.2.3 The Pol II holoenzyme pathway 
This alternative pathway of PIC assembly was first described after the purification of a 
preassembled complex of Pol II with or without a subset of general TF (Ossipow et al., 1995) 
and proteins involved in chromatin remodeling (Cairns et al., 1996), DNA repair (Maldonado 
et al., 1996) and mRNA processing (McCracken et al., 1997). Specifically, PolII and TFIIB, 
TFIIE, TFIIF and TFIIH have been identified in Pol II holoenzyme formation in the absence 
of TFIID. In this pathway, the core promoter-binding factor TFIID is suggested to facilitate 
the entry of Pol II holoenzyme to the promoter region in a process parallel to prokaryotic 
RNA polymerase recruited by the dissociable σ factor.  
Both, the sequential assembly pathway and the Pol II holoenzyme pathway may exist in vivo, 
depending on specific needs for individual gene transcription or transcription efficiency 
(Lemon & Tjian, 2000), as in the suggested process of loop structure formation (cf. 1.5.1). 
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1.6.2.4 The TFIID complex 
In either pathway, the multiprotein complex TFIID is one of the first general TF that binds the 
core promoter and facilitates PIC assembly. Historically, TFIID has been described as a 
TATA-binding factor through in vitro binding assays, but human TFIID seems to act 
primarily through TATA-less promoters in vivo as shown by ChIP-on-chip experiments (Kim 
et al., 2005). Together with the TBP, 13 TBP-associated factors (TAF) have been identified. 
The TBP subunit of TFIID thereby is specified in contacting TATA boxes, allowing TFIID to 
recognize TATA-containing promoters. TATA-less promoters displaying either one of the 
core promoter elements (fig. 6) are thereby recognized by the diversity of TAF subunits of 
TFIID (Pugh & Tjian, 1991). In depths characterization of TAF revealed that TFIID exerts 
potential as a co-activator in transcription, modulating activator function through multiple 
domain interactions. This has been explicitly demonstrated for the transcriptional activator 
SP1. The DNA-binding domain of SP1 specifically interacts with TAF7 of the TFIID 
complex (Chiang & Roeder, 1995), while the SP1 activation domain contacts TAF7 (Hoey et 
al., 1993). Human TAF7 is able to interact with different activators of transcription in 
addition to SP1, such as YY1 and USF, through its N-terminal domain and TAF1 in its central 
region, documenting its co-activator potential by bridging the bound activator to the general 
transcription machinery with simultaneous bending of interlaced DNA regions. These  
TAF-TAF interactions suggest transcriptional activators to function by recruiting TFIID to the 
promoter with subsequent PIC formation (Albright & Tjian, 2000), leading to the concept of 
TAF-dependent activation (fig. 7a). However, some genes do not rely on TAF, and TBP 
serves as a TATA-binding factor without mediation of TFIID in a TAF-independent 
activation (fig. 7b). In the absence of TAF, TBP can function with general cofactors such as 
TFIIA and TFIIH, replacing TAF by submitting signals between activators and the general 
transcription machinery.  
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Figure 7: TAF-dependent and TAF-independent transcriptional activation. 
The schematic representation shows promoter recognition in case of (A) TATA-less promoters and 
(B) TATA promoters. (A) TFIID-mediated promoter recognition is the rate-limiting step (wide arrow) 
facilitated by transcriptional activators. (B) When TBP is used as TATA-recognition factor, Pol II 
recruitment becomes the rate-limiting process. With modifications from Thomas & Chiang, 2006. 
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1.6.3 CpG islands promoters 
The CpG dinucleotide, which resembles a substrate of the DNA methyltransferase, is 
underrepresented in the human genome because of ongoing deamination and thymine 
formation without correction by DNA repair enzymes. Although these mutations seem to take 
place accidentally and at random, extended stretches of DNA (0.5 – 2 kbp) exist that possess a 
relatively high density of CpG dinucleotides, contradicting this principle (Smale & Kadonaga, 
2003). CpG islands remain mostly unmethylated in different tissues and stages of 
development compared to other DNA sequences and are associated with an accessible 
chromatin structure (Antequera & Bird, 1993). This characteristic feature has been suggested 
to be the cause of common CpG promoter bidirectionality after parasitic DNA insertion in 
close proximity (Kalitsis & Safferi, 2009). In humans, the percentage of CpG-associated 
promoters has been reported to be 88% (Kim et al. 2005), suggesting that CpG islands may 
play a more general role in gene expression than previously anticipated. Despite the high 
prevalence of CpG islands promoters, the elements that are essential for their core promoter 
function remain poorly defined. They are often characterized by the presence of multiple TSS 
that span a region of 100 bp or more. The TSS can co-localize with sequences exhibiting 
homology to the Inr consensus sequence but have also been reported to function 
independently of this core promoter element. One common feature of CpG islands is the 
presence of multiple binding sites for SP1. TSS are often located 40–80 bp downstream of the 
SP1 consensus sites and SP1 is suggested to direct the basal machinery to form a PIC within a 
loosely defined sequence portion (cf. 5.3). As discussed above, TFIID subunits are capable of 
core promoter recognition interact with the sequences most compatible with their DNA 
recognition motifs within that region. Binding of basal factors is strongly dependent on 
recruitment by activator proteins (fig. 6) bound to distal promoter elements. Activators such 
as SP1, may recruit TFIID to the core promoter, via a mechanism that is less dependent on the 
affinity of TFIID for the core promoter. Furthermore, active binding of SP1 in addition to 
promoter activation plays a key role in protecting CpG islands from de novo methylation 
(Brandeis, 1994). 
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1.7 Linkage and association studies 
 
1.7.1 Family-based linkage analyses 
The prevalence of complex genetic diseases results from interactions between various 
environmental factors and genetic variations. Identification of alleles affecting disease risk 
will help to better understand disease aetiology and pathophysiology. Genome-wide linkage 
analysis using polymorphic loci or markers such as SNPs spread across the genome is one 
common approach to map disease-associated genes. It is the simplest form of genetic 
mapping, measuring correlated segregation of Mendelian inherited markers for a trait of 
interest in families. Given meiotic recombination, linked markers are supposed to be located 
in close proximity to a disease-influencing gene. In this setting, disease-associated genomic 
regions for a continuous phenotype are identified that more likely harbour a causal genetic 
variant contributing to the trait. While linkage analysis has been proven to be successful in 
mapping genes underlying mono- or oligogenic diseases, the approach has its limitations in 
detecting genes underlying multifactorial complex traits. Another limitation of linkage 
mapping in humans is the recruitment of a sufficient number of affected families. 
 
1.7.2 Population-based association analyses 
One widely used method for identification of genes involved in complex disease 
pathophysiology is to compare allele or genotype frequencies of a given variant, mainly 
SNPs, between two groups (Couzin-Frankel, 2010). If a particular allele in either group is 
observed with higher frequency than expected by chance, it suggests an association with the 
disease or trait of interest. Most often, the candidate allele serves as a marker rather than 
representing the functional (causal) variant influencing the disease phenotype. The correlation 
between genetic variants and trait differences is most often assessed in case/control samples 
on a population scale. Until now, candidate gene association studies were performed to 
dissect common variants within genes of previously identified linkage regions or putative 
diseased pathways. However, association studies based on one or few candidate genes 
examine only a small fraction, disregarding the multifactorial nature of complex traits. 
Moreover, the hypothesis-driven approach leads to potential bias in selecting candidate genes. 
The completion of the human genome project and the development of cost-efficient high-
throughput SNP genotyping platforms have set the stage for GWA studies. They represent an 
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important step beyond candidate gene studies, allowing SNP marker queries of the entire 
genome at levels of high resolution, unaffected by prior hypotheses. GWAs are based on the 
common disease/common variant hypotheses suggesting that a distinct number of variants 
with allele frequencies of more than 1% in the observed population contribute to the more 
common forms of human diseases. The number of GWAs is exponentially growing, 
addressing several disease categories including cancer, cardiovascular, autoimmune, 
metabolic, and neurodegenerative diseases, etc. Due to insufficient sample size or random 
errors, associated SNP markers found in GWAs often exhibit a lack of reproducibility and 
suffer from high false positive rates (Manolio et al., 2009). However, newer studies rely on 
very large sample sizes and appropriate statistical features (P-values corrected for multiple 
testing in GWAs) that allow reproducibility of allelic associations (Ehret, 2010). 
 
1.8 Aim and design of the study 
 
BGN was chosen as a candidate gene for CVD with regard to its emerging role in 
atherosclerosis pathophysiology, which has already been proven in appropriate animal 
models. As a multifunctional and proinflammatory component of the ECM in the heart but 
also in the arterial system, BGN is involved in the different steps of atherosclerosis, heart 
disease progression and outcome, etc.  
Individual functional genetic variants and molecular haplotype patterns may account for the 
genetic predisposition to disease traits. Genetic variants that possibly affect the transcriptional 
regulation of BGN may thereby influence local BGN expression and stoichiometric 
availability in a given regulatory context, altering downstream cellular processes.  
To identify genetic variants of the BGN 5’-flanking region within 57 CVD patients of the 
MolProMD study, we performed a systematic screening of patients’ genomic DNA. Rare 
variants with a distribution of ~1% were calculated to be detected with ~80% likelihood, 
analysing 120 chromosomes. Molecular haplotype constellations were identified by individual 
subcloning and resequencing of patients’ DNA. For subsequent in vitro functional analyses of 
variants altering BGN gene regulation, a sufficiently active promoter portion had to be 
determined, in a cell system endogenously expressing BGN, by the use of reporter gene 
assays. Reporter gene assays allow the determination and quantification of transcriptional 
activity of a defined promoter portion cloned into a promoter-less reporter gene vector. 
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Observed reporter gene expression is thereby explicitly driven from the inserted promoter 
fragment. In addition, the selected cell system required the transposition of in situ cellular 
processes such as ECM generation and processes of inflammation. Alternative TSS in the 
employed cell lines were assessed by 5'RACE. Using serial 5'-deletion of a sufficiently active 
promoter portion, cell specific cis-regulatory elements were identified. Possible alterations in 
DNA/protein interactions of trans-acting factors at cis-regulatory positions by introduction of 
detected genetic variants were analysed on a first level using computational models for in 
silico TFBS prediction. Co-expression experiments were used to control in vivo potential of 
predicted interacting transcriptional regulators in cell lines. In vitro binding of promoter 
elements by TF, with special respect to allele-specific differences, were assessed by gel shift 
experiments. EMSA competition assays were scheduled to identify interacting proteins. 
Where applicable novel approaches for promoter analyses and identification of TF were 
implemented in the work. 
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2 MATERIAL 
 
2.1 Chemicals 
 
Laboratory chemicals (highest quality) were generally purchased from Merck (Darmstadt), 
Sigma (Steinheim) or Roth (Karlsruhe). Chemicals from different suppliers are listed as 
follows.  
 
Agarose        Biozym, Hess. Oldendorf 
Bacto Agar        Becton Dickinson, Heidelberg 
Bacto Tryptone       Becton Dickinson, Heidelberg 
Bacto Yeast Extract       Becton Dickinson, Heidelberg 
Blocking reagent      Roche Diagnostics, Mannheim 
Biotin dd-UTP      Roche Diagnostics, Mannheim 
Chloroform        Fluka Riedel-de Haën, Seelze 
dNTPs (dATP, dCTP, dGTP, dTTP)    Fermentas, St. Leon-Rot 
Ficoll         Fluka Riedel-de Haën, Seelze 
Glutamin       Gibco, Karlsruhe 
Nonidet P-40 (IGEPAL)      Sigma Aldrich, Schnelldorf 
Poly(dI•dC)       USB, Staufen 
Protease Inhibitor cocktail with EDTA (Complete)   Roche Diagnostics, Mannheim 
Spermidine        Fluka Riedel-deHaën, Seelze 
TGF-β1, human, recombinant    Calbiochem, San Diego, USA 
IL-1β, human, recombinant     Calbiochem, San Diego, USA 
PDGF, human, from platelets    Calbiochem, San Diego, USA 
 
 
 
2 Material 
 
page | 22  
 
 
2.2 Other solutions and reagents 
 
2.2.1 Sera and media 
Dulbecco’s modified eagle’s medium (DMEM)   Sigma, Steinheim 
Dulbecco’s phosphate buffered saline (PBS)   Sigma, Steinheim 
Fetal bovine serum (conditioned)     PAA, Pasching 
Fetal bovine serum, iron supplemented    Cell Concepts, Umkirch 
Roswell Park Memorial Institute 1640 medium (RPMI) Sigma, Steinheim 
 
2.2.2 DNA ladder and protein marker 
Precision Plus Protein Dual Color Standard Plus   BioRad, Munich 
Precision Plus Protein Western C    BioRad, Munich 
GeneRuler 100 bp DNA ladder     Fermentas, St. Leon-Rot 
GeneRuler 1 kb DNA ladder     Fermentas, St. Leon-Rot 
 
2.2.3 Enzymes and antibiotics 
Trypsine-EDTA (0.05%)      Gibco, Karlsruhe 
Ampicillin        Roth, Karlsruhe 
Penicillin/Streptomycine solution     Sigma Chemie, Steinheim 
Spectinomycine       Sigma, Steinheim 
 
2.2.4 Consumables and kits 
BCA Protein Assay Kit      Thermo Fischer, Bonn 
CL-XPosure Film       Thermo Fischer, Bonn 
High Pure PCR Product Purification Kit    Roche Diagnostics, Mannheim 
Immobilon-P Transfer Membrane (PVDF)    Millipore, Bedford, USA 
LightShift Chemiluminescent EMSA Kit    Thermo Fischer, Bonn 
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Lipofectamine 2000       Invitrogen, Karlsruhe 
Luciferase Assay System      Promega, Mannheim 
Magnetic Protein-G beads      Invitrogen, Karlsruhe 
Nanofectin       PAA, Pasching 
Passive Lysis Buffer (5 x)      Promega, Mannheim 
PureLink HiPure Plasmid DNA Purification Kit   Invitrogen, Karlsruhe 
QIAamp DNA Blood Mini Kit     Qiagen, Hilden 
NucleoSpin Plasmid      Macherey-Nagel, Düren  
NucleoSpin RNA II      Macherey-Nagel, Düren 
QIAquick Gel Extraction Kit     Qiagen, Hilden 
QuikChange Multi Site-directed Mutagenesis Kit   Stratagene, Amsterdam, 
The Netherlands 
SuperSignal West Pico Chemiluminescent Substrate Thermo Fischer, Bonn 
Whatman Paper 3MM Chr.      Biometra, Göttingen 
Pipette tips 0.1 µl - 1000 µl      Sarstedt, Nürnbrecht 
Reaction tubes 0.2 ml - 2 ml      Eppendorf, Hamburg 
Biozym, Hess. Oldendorf 
15 ml/50 ml tubes       Greiner, Kremsmünster 
Nunc, Wiesbaden 
Petri dishes        Sarstedt, Nürnbrecht 
Plastics for cell culture      Greiner, Kremsmünster 
PCR plates, microtiter plates     Abgene, Hamburg 
 
2.2.5 DNA-modifying enzymes 
BigDye3.1       Applied Biosystems, 
Foster City, USA 
DNase I       Fermentas, St. Leon-Rot 
Exonuclease I       Fermentas, St. Leon-Rot 
GoTaq DNA Polymerase      Promega, Mannheim 
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Herculase II DNA Polymerase     Stratagene, Amsterdam, 
The Netherlands 
High Fidelity PCR Enzyme Mix     Fermentas, St. Leon-Rot 
Restriction endonucleases      Fermentas, St. Leon-Rot 
RNase H       Fermentas, St. Leon-Rot 
RNase A       Applichem, Darmstadt 
Shrimp Alkaline Phosphatase     Fermentas, St. Leon-Rot 
Superscript III       Invitrogen, Karlsruhe  
RNaseOUT RNase Inhibitor      Invitrogen, Karlsruhe 
T4 DNA Ligase       Fermentas, St. Leon-Rot 
TdT terminal transferase     Roche, Mannheim 
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2.2.6 Antibodies 
 
Table 1: Antibodies 
Antibody Host Dilution Manufacturer 
c-FOS rabbit 1:1000 Santa Cruz, Heidelberg 
CREB/ATF1 rabbit 1:1000 Nanotools, Teningen 
GATA1 rat 1:1000 Santa Cruz, Heidelberg 
PU.1 rabbit 1:1000 Santa Cruz, Heidelberg 
SP1 rabbit 1:1000 Upstate, Schwalbach 
SRF mouse 1:1000 Millipore, Schwalbach 
 
 
 
2.2.7 Plasmids and vectors 
pCRII TOPO cloning vector     Invitrogen, Karlsruhe 
pCR8/GW/TOPO cloning vector    Invitrogen, Karlsruhe 
pGL3-Basic reporter gene vector     Promega, Mannheim 
pGL3-Control reporter gene vector     Promega, Mannheim 
pGL3-Promoter reporter gene vector   Promega, Mannheim 
pGFP reporter gene vector      Amaxa, Cologne 
pRc/CMV expression vector      Dr. Dimitris Kardassis, Heraklion, 
        Greece 
pSP1/CMV expression vector     Dr. Dimitris Kardassis, Heraklion, 
        Greece 
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2.2.8 Bacteria (E. coli) 
 
Strain   Genotype     Manufacturer 
 
DH5α (K12)   F- φ80lacZ∆M15 ∆(lacZYA-argF)   Invitrogen, Karlsruhe 
U169 recA1 endA1 hsdR17(rk-, mk+) 
phoA supE44 thi-1 gyrA96 relA1 λ- 
Mach1   derivatives of E. coli W strains   Invitrogen, Karlsruhe 
∆recA1398 endA1 tonA Φ80∆lacM15 
∆lacX74 hsdR(rK- mK+) 
 
 
2.2.9 Eukaryotic cells 
 
Line   Origin      Reference 
 
COS-7   African green monkey    ATCC no.: CRL-1651 
kidney, fibroblast-like  
EA.hy926  Human vascular endothelium  Edgell et al., 1983 
HEK293T   Human embryonic kidney    ATCC no.: CRL-11268 
THP-1   Human monocytes    ATCC no.: TIB-202 
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2.2.10 Laboratory equipment 
 
Instrument     Specification    Manufacturer 
 
Cell counter     Casy Model TT   Innovatis, Bielefeld 
Centrifuge     Multifuge 3SR  Heraeus, Hanau 
Centrifuge    5415C    Eppendorf, Hamburg 
Centrifuge    5417R    Eppendorf, Hamburg 
Centrifuge     5810R    Eppendorf, Hamburg 
Centrifuge    J2-21M/E   Beckman Coulter, Krefeld 
CO2-Incubator (eukaryotic cells)  MCO-18AIC    Sanyo, Munich 
Coffee maker    TKA1410V   Bosch, Munich 
Developing machine    Optimax    Protec, Oberstenfeld 
Gel electrophoresis chamber   Mini PROTEAN   BioRad, Munich 
Gel electrophoresis chamber   StarPhoresis    Starlab, Ahrensburg 
Gel imaging     AlphaImagerEC   Alpha Innotech Corp, 
San Leandro, USA 
Incubator shaker    Series 25   New Brunswick Scientific, 
Nürtingen 
Luminometer     Sirius V12    Berthold Detection  
Systems, Pforzheim 
Microbiological incubator   B 6120    Heraeus, Hanau 
Microscope     Axiovert 40 CFL   Zeiss, Jena 
pH-Meter     Calimatic 766   Knick, Dülmen 
Spectrophotometer   NanoPhotometer   Implen, Munich 
Power supply     PowerPackBasic   BioRad, Munich 
Sequence detection system   7500 ABIprism   Applied Biosystems, 
Foster City, USA 
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Sonicator    Bioruptor UCD-200  Diagenode, Liège, 
         Belgium 
Sterile hood (bacteria)   Class II type EF  Clean air Techniek B.V., 
Woerden,  
The Netherlands 
Sterile hood (eukaryotic cells)  HS 12     Heraeus, Hanau 
Tank Blot chamber    Mini Trans-Blot Cell   BioRad, Munich 
Thermocycler    PTC-225, PTC-240   MJ Research, Miami, 
DNA Engine Tetrad (2)  USA 
UV-table     Transilluminator   Intas, Göttingen 
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3 METHODS 
 
3.1 Molecular biological methods 
 
General molecular methods were performed as described in “Molecular Cloning” (Sambrook 
& Russel, 2001). Variations in protocols are indicated where appropriate. 
 
3.1.1 Preparation of genomic DNA 
Genomic DNA was extracted from mononuclear cells or cell lines using the QIAamp DNA 
Blood kit (Qiagen) according to manufacturers’ instructions. Briefly, 200 µl of human whole 
blood (EDTA-treated) or 5 x 106 cultured cells were mixed with 20 µl Proteinase K and 200 
µl binding buffer, incubated at 56°C for 10 min and loaded to the spin column. After two 
washing steps, DNA was eluted with dH2O (pH 7 – 8.5) or TE. Genomic DNA was held at 
4°C and stored at -20°C. 
 
3.1.2 Preparation of total RNA 
RNA was extracted from cultured cells using the NucleoSpin RNA II kit (Macherey-Nagel) 
following the manufacturers’ instructions. Cells (5 x 106) were lysed by adding 350 µl lysis 
buffer/1% β-mercaptoethanol. The lysate was cleared by filtration through filter columns and 
350 µl ethanol was added to adjust binding conditions. The lysate was loaded onto RNA 
binding column followed by desalting of the membrane. DNA was removed from the column 
by incubation with DNase for 15 min. Washed thrice, total RNA was eluted in RNase-free 
water and stored at -80°C. 
 
3.1.3 Preparation of plasmid DNA 
Plasmid DNA from E. coli cultures (1.5 ml) for cloning was obtained by use of the 
NucleoSpin Plasmid kit (Macherey-Nagel) following manufacturers’ instructions. Pelleted 
cells were resuspended and lysed for 5 min at RT. After addition of neutralization buffer, 
lysate was cleared by centrifugation. DNA was bound to silica membrane and washed twice. 
Ethanol was qualitatively removed by centrifugation before elution of plasmid DNA. 
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Alternatively and in case of bacterial artificial chromosome (BAC) preparation was performed 
by alkaline lysis with SDS (Birnboim & Doly, 1979).  
Transfection grade plasmid DNA of highest quality without endotoxins was preparated from 
100 ml E. coli cultures using the PureLink HiPure Plasmid DNA Purification kit (Invitrogen) 
according manufacturers’ instructions. Cells were spun down, resuspended and lysed with 
simultaneous RNase A treatment (5 min). Lysate was cleared by precipitation and 
centrifugation (12000 x g, 10 min, RT). Supernatant was routinely cleared from bacterial 
endotoxins using a separate endotoxin removal protocol (Buffer A and B). The cleared lysate 
was loaded onto an anion exchange column, washed and eluted by gravity flow. Eluate was 
precipitated by addition of isopropanol (70% v/v) and centrifugation (15000 x g, 30 min, 
4°C). DNA was washed in 70% ethanol, centrifuged, air-dried and resuspended in TE buffer. 
Plasmid DNA for transfection was held at 4°C and stored at -20°C. 
 
Endotoxin Removal Buffer A   Endotoxin Removal Buffer B 
50 mM  MOPS, pH 7.0   100 mM  sodium acetate, pH 5.0 
750 mM  sodium chloride   750 mM  sodium chloride 
10% (w/v)  Triton X-100    1% (w/v)  Triton X-100 
10% (v/v)  isopropyl alcohol 
 
3.1.3.1 Quality and quantity control of nucleic acids 
Concentration and purity of nucleic acids was measured photometrically using a 
nanophotometer (Implen). Identity and potential contamination of plasmid DNA was 
routinely tested by hydrolysation with selected restriction enzymes and automated 
sequencing.  
 
3.1.4 Polymerase Chain Reaction (PCR) 
PCR was performed with variations according to Mullis et al. (Mullis et al., 1990). For 
standard applications, GoTaq DNA polymerase (Promega) was used. To guaranty amplicon 
sequence identity with template DNA for cloning of transfection vectors, a Taq/Pfu 
proofreading enzyme mix was used (High Fidelity Mix, Fermentas; Herculase II, Stratagene). 
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Standard PCR reaction contained: 
5 ng   of genomic DNA 
10 µM  of each primer 
200 µM  of each dNTP 
1 x   polymerase buffer 
2 mM  MgCl2 
0.6 U   DNA polymerase 
add nuclease free water to 25 µl 
 
Enhancing additives were used where appropriate to reduce the formation of secondary 
structures (1 M Betain, 2 – 10% DMSO, 1/3 deazaGTP/dGTP) or to stabilize DNA 
polymerase (0.1 - 1% Triton X-100, Tween 20, NP - 40). 
 
 
Standard PCR program: 
A: Initial denaturation  95°C, 5 min 
B1: Denaturation   95°C, 1 min 
B2: Annealing   x°C, 45 sec 
B3: Elongation   72°C, 1 min/kb 
C: Final elongation  72°C, 10 min 
 
Modifications of the program were applied where appropriate. 
 
Calculation of oligo Tm was performed using the algorithm of Chester & Marshak (Chester & 
Marshak, 1993): 
 
 
 
 
otideoligonucle oflenght 
650
 -0.41)x content ~%GC  (69.3 +
25 – 35 
cycles 
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Touch down PCR:  
To enrich specific PCR products, annealing temperatures was gradually decreased for 
maximum annealing stringency. The annealing temperature was set 5 - 10°C over primer 
annealing temperature and reduced by 2°C every second cycle until calculated annealing 
temperature was reached, followed by 25 cycles at final annealing temperature. 
 
Nested PCR:  
To amplify weak PCR signals and to generate specific fragments from a mixture of unspecific 
amplicons, a second set of inner or nested primers was used. Amplified PCR product was 
either used directly as template (1 µl) or after extraction from agarose gels (3.1.11). 
 
3.1.5 cDNA synthesis 
Generation of cDNA was performed using Superscript III (Invitrogen) according to the 
manufacturer. Total RNA (500 ng – 5 µg, extracted as described in 3.1.2) were reversely 
transcribed using either 1 µl of oligo(dT) or 2 pmol of gene-specific primer in presence of a 
RNase inhibitor (RNaseOUT, Invitrogen) for 60 min at 50°C. Reaction temperature was 
increased to 55°C for gene-specific primers. Reaction was inactivated by heating at 70°C for 
15 min. Prior to amplification of longer PCR targets (>1 kb) and in case of 5'RACE 
experiments, complementary RNA was removed by incubation with RNase H (2 units, 20 
min, 37°C). Integrity of cDNA was routinely controlled by diagnostic PCR for hRP27. 
 
3.1.6 5'RACE 
RACE PCR was performed as described previously (Frohman, 1993). All experimental steps 
were performed within the same day, without freezing of the generated cDNA to achieve 
maximum accuracy at TSS identification. Briefly, total RNA was extracted (3.1.2) and first 
strand cDNA was generated (3.1.5) using a BGN specific antisense primer, followed by 
poly(A)tailing of the 3'-end using terminal desoxynucleotidyl transferase (TdT). A 
homopolymeric d(T)-anchor primer, complementary to the 3'-poly(A) tail, and an antisense 
primer located within the gene were used to amplify the first PCR product. Nested primer 
were used to increase the amount of PCR product for subsequent sequencing (tab.2).  
 
3 Methods 
 
page | 33  
 
Table 2: Oligonucleotide sequences for 5'RACE 
Description Sequence 5' to 3' Position Ref. Accession # 
BGN RT AGCTTCCTGGCTCTGCCTCC Exon 2 NT_011726.13 
dT-anchor primer GACACGCGTATCGATGTCGACTTTTTTTTTTTTTTTT  -  - 
Adaptor primer GACCACGCGTATCGATGTCGAC -   - 
 
First strand cDNA synthesis reaction using SuperScript III (Invitrogen) 
2 µg   total RNA 
2 pmol  gene-specific primer 
500 µM  of each dNTP 
ddH2O to 13 µl 
Mixture was heated to 65°C for 5 min and incubated on ice for at least 1 min. 
4 µl   synthesis buffer 
5 mM  DTT 
1 µl  RNaseOUT RNase inhibitor (Invitrogen) 
1 µl   SuperScript III reverse transcriptase 
Mixture was incubated for 60 min at 55°C. 
RNA complementary to the cDNA was removed by addition of RNaseH (2 U) and incubation 
at 37°C for 20 min. 
 
Poly(A) tailing  
16.5 µl  purified cDNA  
5 µl   reaction buffer   
2.5 µl  dATP (2 mM)    
Mixture was incubated at 94°C for 3 min and chilled on ice.  
1 µl   TdT (80 U/µl)    
Incubation at 37°C for 30 min followed by heat inactivation for 10 min at 70°C. 
PCR reaction was performed as described (3.1.4) using gene-specific primer and  
d(T)-anchor primer at 55°C for 35 cycles. 
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3.1.7 DNA/RNA-modifying reactions 
3.1.7.1 Hydrolysation with bacterial endonucleases 
Hydrolysation with endonucleases was conducted using 100 - 500 ng DNA and 1 U 
restriction enzyme. H2O and 10 x reaction buffer were added to a total volume of 20 µl, 
incubated for 1 hr at 37°C and heat-inactivated at 70°C for 10 min. 
 
3.1.7.2 Dephosphorylation of DNA 
Shrimp Alkaline Phosphatase (SAP) was used for dephosphorylation of 5'-ends of linearized 
plasmid DNA to disable re-ligation. One unit of SAP, dH2O and 10 x reaction buffer were 
added to the digestion reaction (cf. 3.1.7.1) to a total volume of 25 µl. Reaction mixtures were 
incubated at 37°C for 30 min and heat-inactivated for 10 min at 65°C.  
 
3.1.7.3 Biotinylation of oligonucleotides for EMSA experiments 
Single-stranded oligonucleotides (~30 bp; IBA, Göttingen) for EMSA experiments were 
synthesized at a minimum coupling efficiency of > 98.5% and purified twice by high pressure 
liquid chromatography. Oligonucleotides were 3'-biotinylated with biotin-16-ddUTP (Roche) 
using TdT. 5 pmol of each oligo were labelled in a reaction mix containing 2 mM CoCl2, 500 
pmol biotin-16-ddUTP, and 60 U TdT at 37°C for 30 min. Labelled probes were chloroform 
extracted and centrifuged twice (2 min, 14000 x g, RT). Specific annealing of 
oligonucleotides (20 fmol) was achieved by denaturation at 95°C for 10 min in 100 mM 
NaCl, followed by slow over night cool down to RT. Double-stranded competitors were 
generated using a concentration of 2 pmol of each unlabeled primer. Annealing quality and 
signal intensity of identical probes holding single base pair mutations were controlled 
routinely by gel electrophoresis. 
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3.1.8 Agarose gel electrophoresis 
Agarose concentrations of 0.5% to 3% were applied in 1x TAE buffer, depending on fragment 
sizes. 
 
50 x TAE      6 x Loading buffer 
2 M   Tris base    0.02% (w/v)   bromphenol blue 
50 mM  EDTA    0.02%  (w/v)   xylene cyanol 
adjusted to pH 8.0 with acetic acid  30% (v/v)   glycerol 
      20 mM   Tris-HCl, pH 7.6 
2 mM    EDTA 
 
For visualizing DNA double-strands, 0.05 µg/ml ethidium bromide (EtBr) was added to the 
gel solution. Longer fragments (>5 kbp) generated for cloning after gel extraction were 
stained using a Crystal Violet (Sigma) solution (0.01% w/v in 1 x TAE) and were cut from 
gels without the use of UV light to prevent DNA strand breaking. 
 
3.1.9 Site-directed mutagenesis 
Site-directed mutagenesis was used for selective introduction of genetic variants into the 
respective reporter gene vectors using a highly efficient commercial system (QuikChange 
Multi Site-directed Mutagenesis Kit, Stratagene). Allelic variants -578A, -151A, +94T were 
introduced into BGN promoter fragments as follows: denaturation of input vector wt DNA 
was followed by annealing and extension of the mutagenic primers (tab. 3), and ligation of 
nicks. Methylated and hemimethylated DNA was digested with endonuclease DpnI (60 min, 
37°C) followed by bacterial transformation. When indicated, up to three mutations at different 
sites were performed in a single reaction. 
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Standard reaction       Standard mutagenesis PCR 
2.5 µl   QuikChange Multi reaction buffer   Initial denaturation  95°C, 5 min 
0.5 µl   Quik Solution     Denaturation   95°C, 1 min 
100 ng  template DNA     Annealing   55°C, 1 min 
100 ng  of each mutagenic primer    Elongation   65°C,  
1 µl   dNTP mix         (2 min/1 kb) 
1 µl   QuikChange Multi enzyme blend   30 cycles 
 
Table 3: Oligonucleotide sequences for site-directed mutagenesis 
Description Sequence 5' to 3' Position Ref. Accession # 
BGN MUT -578A AAGGGAAGAAAGTCTAGAGTGGAAGGGAGGG -593 NT_011726.13 
BGN MUT -151A GAAGCTGCCAGGGGGACCGGGAAGCCTGCCC -136 NT_011726.13 
BGN MUT +94T CACCACCCCAGCCCTCCAACTAGTCAGCCT +79 NT_011726.13 
 
 
3.1.10 Construction of reporter gene plasmids 
Promoter wt fragments were generated using MolProMD (not ECTIM) patients genomic 
DNA. For the analysis of the three BGN MolHaps, a 1025 bp fragment was generated using 
primer at position -893 (upstream TSS1) and +132. Genetic variants were introduced by  
site-directed mutagenesis (cf. 3.1.9) yielding constructs pBGN-MoLHap1/luc, pBGN-
MolHap2/luc, pBGN-MolHap3/luc. Deletion constructs of the BGN 5'-flanking region were 
amplified using one antisense primer at position +162 bp and sense primers generating 
constructs shown in fig. 8. For all deletion constructs, genomic DNA representing the wt 
sequence was used as template. 
For transient transfection assays, the generated PCR fragments were introduced in  
5'-3'-orientation into the promoter-less luciferase reporter gene vector pGL3-Basic (Promega) 
using the Gateway cloning system (Invitrogen). This highly efficient cloning technique is 
based on site-specific recombination properties of bacteriophage λ (Landy et al., 1989). 
Recombination events occur at specific attachment sequences on phage DNA (attP) and 
bacteria DNA (attB). Gel extracted PCR fragments were primarily cloned into entry vector 
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pCR8/GW/TOPO where the fragment is flanked by attL sequences, and transformed into 
competent Mach1 bacterial cells (cf. 3.3.1.2). After plasmid preparation and purification (cf. 
3.1.3), the entry clone was incubated with the modified pGL3-Basic destination vector 
carrying artificial attR sites. Addition of the LR Clonase enzyme results in the exchange of 
the Gateway cassette in combination with the insert of interest. Generated plasmids were 
double digested with selected, sequence-specific restriction endonucleases (3.1.7.1) followed 
by agarose gel electrophoresis to verify 5'-3'-orientation and correct insert size. All generated 
vectors were directly sequenced (cf. 3.1.12) to ensure sequence accuracy and identity. 
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Figure 8: Schematic representation of deletion constructs of the human BGN promoter.  
Deletion constructs were cloned into the pGL3-Basic vector system (Promega). This vector does not 
possess promoter activity of its own but features a luciferase cassette adjacent to the multiple cloning 
site. Transcriptionally active promoter fragments result in the expression of the luciferase protein, 
permitting measurement of promoter activity in relative light units. Sequence positions are shown 
according to TSS1. Luc: luciferase. 
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Figure 9: pGL3-System vector circle maps.  
The pGL3-Basic vector lacks eukaryotic promoter and enhancer sequences, pGL3-Control vector 
contains SV40 promoter and enhancer sequences, the pGL3-Promoter vector contains an SV40 
promoter upstream of the luciferase gene. Ampr: gene conferring ampicillin resistance in E. coli; luc+: 
cDNA encoding the modified firefly luciferase; f1 ori: origin of replication derived from filamentous 
phage; ori: origin of replication in E. coli. Arrows within luc+ and the Ampr gene indicate the direction 
of transcription; the arrow in the f1 ori indicates the direction of ssDNA strand synthesis. 
© Promega, 
technical manual
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Standard pCR8/GW/TOPO cloning reaction   LR Clonase reaction 
1 µl salt solution (1.2 M NaCl, 0.06 M MgCl2)   100 ng entry vector 
1 µl pCR8/GW/TOPO cloning vector (10 ng/µl)   150 ng destination vector 
4 µl purified insert       2 µl LR Clonase 
incubation for 5 min at RT,      add 8 µl TE-buffer 
transformation in competent      incubation for 1 hr at 25°C 
Mach1 bacterial cells      add 1 µl Proteinase K 
incubation for 10 min at 37°C 
 
Table 4: Oligonucleotide sequences for promoter constructs 
Description Sequence 5' to 3' Position Ref. Accession # 
BGN MolHap SS GCTAGCCAGTGTCGTACTAAGGACCT -893 NT_011726.13 
BGN MolHap AS CCCGGGTGGAGAGGGGAGGCGCCA +132 NT_011726.13 
BGN -1318/+162 SS ACAGTTTGGTCAAGGTGCCA -1318 NT_011726.13 
BGN -1231/+162 SS CATGCCCCCAGGTAGAGC -1231 NT_011726.13 
BGN -1098/+162 SS GATGCCGCCTCTCTCTAGC -1098 NT_011726.13 
BGN -935/+162 SS GCTCTTGCTGAGGGAAGAAG -935 NT_011726.13 
BGN -701/+162 SS GAAGACTGACTCGCTGGAT -701 NT_011726.13 
BGN -386/+162 SS GTTTGAGTGAGTGCGAGTGT -386 NT_011726.13 
BGN -39/+162 SS TGCCCAGCCTTTAGCCTC -39 NT_011726.13 
BGN +162 AS CTGAGGAGGCAGCTTGAAG +162 NT_011726.13 
 
 
 
3.1.11 Purification of PCR products 
Purification of PCR products for sequencing, cloning or generation of probes was performed 
by extraction from agarose gels or directly from PCR reactions. 
Gel extraction was performed using QIAquick Gel Extraction Kit (Qiagen). DNA fragments 
(between 70 bp and 10 kbp) were excised from low agarose gels, mixed with solubilization 
buffer QG (pH 7.5) and heated for 10 min at 50°C. If changes in colour of buffer QG 
occurred, 10 µl of 3 M sodium acetate, pH 5.0 were added to restore optimal binding pH. 
Samples were mixed with one gel volume of isopropanol (100%) loaded onto column silica 
membranes (≤400 mg agarose) and washed twice. DNA was eluted in buffer EB (10 mM 
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Tris-HCl, pH 8.5). PCR product purification was performed using the High Pure PCR Product 
Purification Kit (exclusion limit 100 bp; Roche). Reactions (up to 100 µl) were mixed with 
binding buffer and loaded onto a silica membrane column. After two washing steps, the DNA 
was eluted in 10 mM Tris-HCl, pH 8.5. 
For sequencing reactions, a rapid one-step PCR clean-up was performed using the ExoSAP 
protocol. A mixture of Exonuclease I and Shrimp Alkaline Phosphatase (SAP) (both 
Fermentas) was used to digest small single-stranded fragments (e.g. primers) and to remove 
dNTPs. 
 
ExoSAP mixture 
20 U    Exonuclease I (E. coli) 
10 U    Shrimp Alkaline Phosphatase (SAP) 
add dH2O to 100 µl 
PCR products (5 µl) were prepared with 1 µl of ExoSAP mix and incubated at 37°C for 30 
min followed by heat-inactivation for 15 min at 80°C.  
 
3.1.12 Sequencing 
Samples were sequenced for detection and localization of genetic variants in the MolProMD 
study (not ECTIM), and to control for sequence identity of DNA fragments and plasmid 
constructs using an automated ABI 3730 fluorescence sequencer with BigDye terminator 
chemistry (PE Applied Biosystems). 
 
Standard sequencing reaction 
5 - 50 ng   purified PCR fragment or 120 ng plasmid DNA 
1.6 µM   sequencing primer 
2 µl   5 x BigDye buffer 
1 µl    BigDye3.1 (Applied Biosystems) 
add dH2O to 10 µl 
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3.1.13 EMSA 
To reveal in vitro DNA/protein interactions, EMSA experiments were performed. 
Oligonucleotides (tab. 4) representing the DNA sequence of interest were purchased from 
IBA (Göttingen) with a maximum coupling efficiency of 98.5%. Oligonucleotides were  
3'-biotinylated with biotin-16-ddUTP (Roche) using TdT (cf. 3.1.7.3) for detection with anti-
biotin antibodies. Protein binding to the applied probe is visualized by a shifted band in lanes 
containing protein extract in comparison to the control lane representing the unbound DNA 
probe. Per standard reaction, 5 µg nuclear protein extract was incubated with 500 ng 
presheared poly (dI●dC) as non-specific competitor, 250 mM Betaine, and a 200-fold molar 
excess of unlabeled oligonucleotide as specific competitor for 5 min at RT. After addition of 
the labelled probe, reactions were incubated for 15 min at RT. Probes and bound complexes 
were separated on a 6% native PAGE (0.5x TBE; 100 V), and blotted afterwards onto PVDF 
membranes (cf. 3.2.6) (0.5x TBE; 100 V; 60 min). DNA probes were cross-linked to the 
membrane by UV-light (312 nm) for 10 min. 
 
4 x binding buffer      6% PAGE 
20 mM  MgCl2     2 ml   Acrylamid-Bis 30% 
240 mM  KCl      1 ml   5 x TBE 
40 mM  HEPES/KOH, pH 7.9   83.7 µl  APS, 10% 
5 mM   spermidine     3.7 µl   TEMED 
16% (w/v)  Ficoll  
 
5 x TBE 
45 mM  Tris base 
45 mM  boridic acid 
10 mM  EDTA 
 
Visualization of probes was achieved using the Chemiluminescent Nucleic Acid Detection 
Module (Thermo Fischer). Membranes were blocked in blocking buffer containing 
streptavidin-horseradish peroxidase conjugate. After washing and equilibration, membranes 
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were incubated in substrate working solution (luminol/enhancer and peroxidase solution). 
Membranes were than exposed to CL-X Posure Film (Thermo Fischer).  
 
 
Table 5: Oligonucleotide sequences of EMSA probes 
Description Sequence 5' to 3' Position Ref. Accession # 
BGN-578A SS AGGGAAGAAAGTCTGAAGTGGAAGGGAGGGCACAGG -593 NT_011726.13 
BGN-578A AS TCCCTTCTTTCAGACTTCACCTTCCCTCCCGTGTCC -593 NT_011726.13 
BGN-578G SS AGGGAAGAAAGTCTGGAGTGGAAGGGAGGGCACAGG -593 NT_011726.13 
BGN-578G AS TCCCTTCTTTCAGACCTCACCTTCCCTCCCGTGTCC -593 NT_011726.13 
BGN-151G SS GCTGCCAGGGGGGCCGGGAAGCCTGCCCCCT -163 NT_011726.13 
BGN-151G AS CGACGGTCCCCCCGGCCCTTCGGACGGGGGA -163 NT_011726.13 
BGN-151A SS GCTGCCAGGGGGACCGGGAAGCCTGCCCCCT -163 NT_011726.13 
BGN-151A AS CGACGGTCCCCCTGGCCCTTCGGACGGGGGA -163 NT_011726.13 
BGN+94G SS GCCCACCACCCCAGCCCGCCAACTAGTCAGCCT +77 NT_011726.13 
BGN+94G AS CGGGTGGTGGGGTCGGGCGGTTGATCAGTCGGA +77 NT_011726.13 
BGN+94T SS GCCCACCACCCCAGCCCTCCAACTAGTCAGCCT +77 NT_011726.13 
BGN+94T AS CGGGTGGTGGGGTCGGGAGGTTGATCAGTCGGA +77 NT_011726.13 
BGN-151MUT 
SS GCTGCCATGGTGGCCGGGAAGCCAGCACCCT -163 NT_011726.13 
BGN-151MUT 
AS CGACGGTACCACCGGCCCTTCGGTCGTGGGA -163 NT_011726.13 
AP-1 SS 
consensus CGCTTGATGACTCAGCCGGAA - Lee et al., 1987a 
AP-1 AS 
consensus GCG AACTACTGAGTCGGCCTT - Lee et al., 1987a 
SP1 SS 
consensus ATTCGATCGGGGCGGGGCGAGC - 
Kodonaga et al., 
1987 
SP1 AS 
consensus TAAGCTAGCCCCGCCCCGCTCG - 
Kodonaga et al., 
1987 
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3.1.14 ChIP 
To access the binding of transcription factors to DNA sequences of interest in vivo, ChIP 
assays were performed using a modified protocol (Boyd et al., 1998; Liu et al., 2000). 
Proteins interacting with the DNA were crosslinked and bound chromatin was precipitated 
using selected specific antibodies. PCR amplification was used to identify the segment of the 
genome associated with the protein. A total of about 107 cells were fixed by adding 
formaldehyde to a final concentration of 1% (v/v) and incubated for 30 min at RT. Cells were 
washed twice with cold PBS (Sigma) and lysed. Cellular debris was removed by 
centrifugation. Isolated nuclei were lysed followed by sonication using a Bioruptor 
(Diagenode; intensity: high, interval: 0.5, 30 min) with resulting chromatin length of ~300 bp. 
Fragment size was routinely controlled on agarose gels. After centrifugation the supernatant 
was incubated for 30 min (4°C) with rabbit pre-immune serum followed by incubation (30 
min, 4°C) with freshly prepared (blocked with BSA and tRNA, 1 hr, 4°C) magnetic Protein-G 
beads (Invitrogen). After centrifugation, supernatant was transferred to low-binding tubes and 
3 µg of specific antibody was added, followed by overnight incubation. Magnetic Protein-G 
beads were added the next day (10 µl, 4°C, for 3 hrs). After extensive washing the 
antibody/protein/DNA complex was eluted from the beads, followed by removal of 
formaldehyde crosslinks and protein digestion with proteinase K (67°C over night). DNA was 
prepared by phenol/chloroform/isoamyl alcohol extraction and used for PCR analysis. 
 
Cellular lysis buffer  Nuclear lysis buffer  Dilution buffer 
10 mM Tris pH 8.0  50 mM Tris pH 8.0  20 mM Tris pH 8.0  
10 mM NaCl   10 mM EDTA  2 mM EDTA  
0.2% (v/v)NP-40  1% (w/v) SDS  150 mM NaCl  
Roche Complete  Roche Complete  1% (w/v) Triton X-100 
proteinase inhibitor  proteinase inhibitor  Roche Complete 
        proteinase inhibitor  
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Wash buffer I   Wash buffer II  Wash buffer III 
20 mM Tris pH 8.0  10 mM Tris pH 8.0  20 mM Tris pH 7.6  
2 mM EDTA   1 mM EDTA   50 mM NaCl  
50 mM NaCl   0.25 M LiCl 
1% (w/v) Triton X-100 1% (v/v) NP-40  Elution buffer 
0.1% (w/v) SDS  1% (w/v) Ceoxycholic  100 mM NaHCO3 
Roche Complete  acid    1% (w/v) SDS 
proteinase inhibitor 
 
Table 6: Oligonucleotide sequences for ChIP 
   
Description Sequence 5' to 3' Position Ref. Accession # 
BGN ChIP -28_+78 SS AGCCTCCCGCCCGCCGCCT -28 NT_011726.13 
BGN ChIP -28_+78 AS CGCACGTCTATCTGTCCGGTG +78 NT_011726.13 
BGN ChIP -918_-806 SS AGGGGACACTACGGGACAG -918 NT_011726.13 
BGN ChIP -918_-806 AS TTACCCCACCAAGACTC GC -806 NT_011726.13 
BGN ChIP -1164_-1066 SS CGGTTGAGTGATGGCACTG -1164 NT_011726.13 
BGN ChIP -1164_-1066 AS GGAGAGAGGGGTGGCTAGAG -1066 NT_011726.13 
BGN ChIP G-578A SS GATCGGGGCCTCTTTTTAAG -610 NT_011726.13 
BGN ChIP G-578A AS TAGCTGTTGTGGATTTCTGG -511 NT_011726.13 
BGN ChIP G-151A SS CGTCTACAAGAAAATTGCTC -191 NT_011726.13 
BGN ChIP G-151A AS GGGGAGGGAGGAAAGGAG -77 NT_011726.13 
BGN ChIP G+94T SS TGCCCAGGAGTGAGTAGCTG +14 NT_011726.13 
BGN ChIP G+94T AS AGGCGCAGGCTGACTAGTTG +115 NT_011726.13 
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3.2 Protein biochemical methods 
 
3.2.1 Preparation of proteins 
Crude protein extracts were prepared from cell culture by scraping cells in presence of lysis 
buffer. Cellular debris was removed by centrifugation (12000 x g, 5 min, 4°C). Pre-heated 
SDS-PAGE sample buffer was added to supernatants and heated to 95°C for 5 min. Samples 
were chilled on ice and loaded directly onto a gel or kept frozen at -20°C until used. 
 
Lysis buffer       4 x SDS sample buffer 
20 mM  imidazole, pH 6.8    200 mM  Tris-HCl, pH 6.8 
100 mM  KCl      8% (w/v)  SDS 
1 mM   MgCl2      0.4% (w/v)  bromphenol blue 
10 mM  EGTA     40% (v/v)  Glycerol 
0.2% (v/v)  Triton X-100 
10 mM  NaF 
1 mM   sodium vanadate 
1 mM   sodium molybdate 
10 mM  sodium pyrophosphate 
25 mM  β-glycerophosphate 
 
3.2.2 Isolation of nuclear proteins 
Nuclear protein extracts were obtained using a modified protocol by Schreiber et al. 
(Schreiber et al., 1989). Briefly, 107 cells were washed twice and harvested by scraping in ice 
cold PBS. Cells were spun down (5000 x g, 2 min, 4°C) and pellets were resuspended in an 
appropriate volume of “low salt” buffer (400–800 µl) and allowed to swell on ice for 15 min. 
After addition of detergent NP-40 (25–75 µl of a 10% solution, depending on cell line), cells 
were vortexed and incubated at room temperature for up to 5 min until cells were lysed. 
Efficiency of this step was controlled by microscopy and optimized for each cell line. The 
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supernatant containing the cytosolic protein fraction was removed by centrifugation (5000 x 
g, 5 min, 4°C). The pellet was resuspended in an appropriate volume of “high salt” buffer 
(50–150 µl, adjusted to pellet size). After 2 hrs of rotation on a wheel at 4°C, cellular debris 
was spun down (24000 x g, 1 hr, 4°C) twice. Supernatant was moved to a fresh tube after the 
first centrifugation step. The nuclear protein fraction was aliquoted on ice, snap frozen in 
liquid nitrogen and kept at –70°C. Nuclear protein fractions were routinely tested for protein 
concentration using BCA assay. Amount of DNA contamination was tested using 
spectroscopy. Integrity of proteins was tested using Coomassie SDS gel staining. 
 
 “low salt” buffer      “high salt” buffer 
10 mM  HEPES, pH 7.9    20 mM  HEPES, pH 7.9 
10 mM  KCl      0.2 mM  EDTA 
1 mM   DTT      1 mM   DTT 
1.5 mM  MgCl2     420 mM  NaCl 
Roche Complete      1.5 mM  MgCl2 
proteinase inhibitor     0.5 mM  PMSF 
25% (v/v)  Glycerol 
       Roche Complete 
       proteinase inhibitor 
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3.2.3 Protein quantification 
Nuclear extracts were analysed spectrometrically using a sensitive BCA Protein Assay Kit 
(Thermo Fischer) with a high tolerance rate for detergents and salts. Standard curve was 
prepared from bovine serum albumin (BSA).  
 
3.2.4 SDS-Polyacrylamide Gel Electrophoresis (PAGE) 
Protein samples were separated on a 10% SDS gel as described by Rittenhouse & Marcus 
(1984). Proteins were denatured in SDS sample buffer (95°C, 5 min), spun down and chilled 
on ice (5 min). Samples ran on stacking gel (4% polyacrylamide) at 80 V and were separated 
afterwards at 140 V. Running time depended on protein size. A pre-stained marker was used 
to control running of the gel. 
 
Stacking gel (4%)      Running gel (10%) 
560 µl   Acrylamide-bis 30%   2.5 ml   Acrylamide-bis 30% 
675 µl   0.5 M Tris-HCl, pH 6.8   1.9 ml   1.5 M Tris-HCl, pH 8.8 
675 µl   0.5 M imidazole, pH 6.8   75 µl   SDS, 10% 
75 µl   SDS, 10%     5 µl   TEMED 
5 µl   TEMED     25 µl   APS, 10% 
40 µl   APS, 10%    add dH2O to 7.5 ml 
add dH2O to 4.2 ml 
 
1 x SDS running buffer 
25 mM  Tris base 
192 mM  glycine 
1% (w/v)  SDS 
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3.2.5 Coomassie blue staining 
Protein bands were visualized by incubation of the gel in Coomassie blue staining solution  
(1 hr), followed by destaining until background was minimized. Gels were kept in storage 
solution and dried when required. 
 
Coomassie staining solution 
0.25% (w/v)   Coomassie Brilliant Blue R-250 
45% (v/v)   methanol 
10% (v/v)   acetic acid 
add dH2O 
 
Destaining solution      Storage solution 
45% (v/v)   methanol     5% (v/v)  methanol 
10% (v/v)   acetic acid     5% (v/v)  acetic acid 
add dH2O       add dH2O 
 
3.2.6 Western Blot (tank blot) 
After separation on SDS gels, proteins were blotted onto PVDF membranes (Immobilon-P, 
0.45 µm, Millipore) following the Towbin tank blot protocol (Towbin et al., 1979). PVDF 
membranes were activated in methanol and equilibrated in blotting buffer. Gel and membrane 
were placed with two layers of Whatman paper and fibre pads inside a gel holder cassette, 
avoiding any air bubbles and placed into the pre-cooled blotting buffer tank. Blots were run 
for 1 hr at 100 V using cooling units.  
 
1 x Blotting buffer 
25 mM  Tris base 
192 mM  glycine 
10% (v/v)  methanol 
adjusted to pH 7.6 
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Membranes were saturated in blocking solution over night (4°C). Proteins of interest were 
detected by immunodetection using specific primary antibodies (cf. 2.2.6). Membranes were 
incubated with primary antibodies in blocking solution for 1 hr and with HRP-coupled 
secondary antibodies for 45 min at RT with gentle agitation. After extensive washing, 
membranes were incubated for 5 min in SuperSignal West chemiluminescent substrate (Pico 
or Femto, Thermo Scientific) and exposed to CL-X Posure Film (Thermo Fischer). 
 
Blocking solution     Wash solution (1 x TBS-T) 
0.5% (w/v)  casein     100 mM  Tris base 
in 1 x TBS-T, pH 7.6    1.5 mM  NaCl 
filtered through 320 mm filter  0.03% (v/v)  Tween-20 
(Schleicher & Schuell, Dassel)  adjusted to pH 7.6 
 
 
3.3 Cell biological and microbiological methods 
 
3.3.1 Prokaryotic cells 
Bacteria were used to generate and amplify plasmid DNA and cultured at 37°C either in LB 
Medium or on LB Agar plates. Antibiotics were added for specific selection of transformed 
bacteria. Glycerol cultures (15% (v/v) glycerol) were snap frozen in liquid nitrogen and stored 
at –80°C without antibiotics. 
 
LB Medium      LB Agar 
10 g  Bactotryptone    15 g Bacto agar in 1000 ml LB Medium 
10 g  Sodium chloride    add appropriate antibiotics after cool down to  
5 g  Yeast extract     56°C 
add dH2O to 1000 ml, pH 7.0     
autoclave at 121°C for 20 min    
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3.3.1.1 Generation of chemically competent cells 
Competent bacterial cells were generated using a modified protocol by Hanahan for 
preparation and transformation of E. coli cells (Hanahan, 1983). 
200 ml of LB Medium were inoculated with bacterial cells and grown to an OD600 of about 
0.4 at 37°C. After 20 min of incubation in an iced water bath with gentle agitation, cells were 
harvested at (4000 x g, 15 min, 4°C,). The pellet was resuspended in 10 ml iced  
MnCl2-transformation buffer, and kept on ice for 10 min, followed by another centrifugation 
step (3000 x g, 10 min, 4°C). The pellet was resuspended in 7.4 ml MnCl2-transformation 
buffer and mixed gently, followed by dropwise addition of 560 µl DMSO. Aliquots of 100 µl 
were prepared on ice and snap frozen in liquid nitrogen. Competent cells were stored at  
–80°C. Transformation efficiency of generated competent cells was routinely tested using 
pUC19 as control vector. 
 
MnCl2-transformation buffer 
10 mM  HEPES, pH 6.8 
15 mM  CaCl2 
20 mM  KCl 
55 mM  MnCl2 
 
3.3.1.2 Transformation of competent cells 
An aliquot of competent cells (100 µl) was incubated in an iced water bath for 3 min, mixed 
with 50 ng of transforming DNA (volume ≤5%) and kept on ice for 30 min. Cells were  
heat-shocked at 42°C for 30 sec, and briefly cooled on ice for 2 min. Pre-warmed  
LB-Medium (250 µl) was added and cells were shook for 45 min at 37°C (225 rpm) for 
recovery and expression of the antibiotic resistance marker encoded by the plasmid. Thereof, 
50 and 150 µl were plated onto antibiotic agar plates using a freshly prepared bent glass rod 
and incubated over night at 37°C. 
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3.3.2 Eukaryotic cells 
Eukaryotic cell lines were used to analyse generated reporter gene plasmid containing 
promoter fragments towards their transcriptional activity using transient transfection (cf. 
3.3.2.3). Different stimulatory regimes were tested in cultured cells to detect regulatory 
effects on gene expression. Cells were also used for ChIP experiments (cf. 3.1.14) to identify 
in vivo interactions of proteins with selected chromatin regions. Nuclear proteins extracted 
from eukaryotic cells were used in EMSA experiments (cf. 3.1.13) to analyse DNA/protein 
interactions in vitro. 
 
3.3.2.1 Eukaryotic cell culture 
The human embryonic kidney cell line HEK293T, the vascular endothelial cell line EA.hy926 
and the African green monkey kidney cell line COS-7 were maintained in DMEM containing 
10% (v/v) fetal calf serum (PAA), 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM/ml  
L-Glutamine (all GIBCO). For cultivation of HEK293T iron-supplemented fetal calf serum 
was used (Cell Concepts). The monocytic cell line THP-1 was maintained in RPMI 1640 
medium (Roswell Park Memorial Institute) containing 10% (v/v) fetal calf serum (PAA), 100 
U/ml penicillin, 100 µg/ml streptomycin, 2 mM/ml L-Glutamine and 1 x modified Eagle’s 
medium amino acid solution (Sigma). THP-1 cells were kept at a concentration of 0.5 to 1 x 
106/ml. Differentiation of THP-1 cells was performed by stimulation with 10-8 m PMA for 72 
hrs. For stimulation of cells 0.5 mM 8-bromo-cAMP (Biolog), 10-8 PMA (Sigma) or 5–20 
ng/ml recombinant cytokines TGF-β1, IL-1β and PDGF (Calbiochem) were used. When state 
of confluence was reached, cells were detached from surface by trypsination and splitted at 
appropriate ratios for further cultivation. The number of passages did not exceed 40 in any 
case. 
 
3.3.2.2 Storage 
For long term storage, cells were washed twice with PBS, trypsinated, and transferred to fresh 
medium. After centrifugation, cells were placed on ice and resuspended in fetal calf serum 
containing 10% (v/v) DMSO. Cryo tubes were cooled slowly to –80°C and transferred to 
liquid nitrogen the next day. Thawing of cells was performed in a water bath at 37°C. To 
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remove DMSO from the freezing medium, cells were washed with PBS and transferred into 
pre-warmed medium after centrifugation. 
 
3.3.2.3 Transient transfection 
Cell lines EA.hy926 and THP-1 were transfected using Nanofectin transfection reagent 
(PAA). Nanofectin consists of two components, a positively charged polymer with  
DNA-binding capacity which is embedded into a porous nanoparticle. In case of EA.hy926 
cells, 105 cells/well were plated in a 24-well plate format and transfected the next day after a 
change of medium 2 hrs prior addition of transfection complexes. For both, EA.hy926 and 
THP-1 cells, 1 µg DNA and 3.2 µl Nanofectin solution were diluted in 50 µl NaCl solution 
(150 mM) and incubated for 10 min at RT. Both preparations were mixed and incubated for 
30 min at RT. Transfection complex was added dropwise to cell medium. In case of 
EA.hy926 cells, transfection reagent was removed by change of medium after 4 hrs. Cells 
were harvested 24 hrs post transfection with 100 µl Passive Lysis buffer (Promega). 
Luciferase activity was determined using a Sirius single-tube luminometer (Berthold detection 
systems). The cell lysate/luciferase substrate ratio was routinely 20 µl/75 µl. 
Transfection of the promoter constructs was performed in equimolar amounts of reporter 
vectors using the inert vector p0GH (Nichols Institute) for adjustment of DNA content. The 
pGL3-Control vector in which transcription is driven by the competent SV40 viral promoter 
and additional enhancer served as positive control. Promotorless pGL3-Basic vector served as 
empty vector control. Transfection experiments were repeated at least three times, in 
triplicates for each plasmid. 
 
3.3.2.4 Cotransfection 
Transient overexpression of proteins was used to analyze possible effects on transcription of 
the cotransfected reporter gene vectors containing promoter fragments. Expression vector to 
reporter gene vector ratio was routinely 3:1. In this study, expression vectors for members of 
the C/EBP family, CBP and SP1 were used. 
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3.4 Study populations 
 
The current investigation was based on the Münster Molecular Functional Profiling for 
Mechanism Detection (MolProMD) study. Genomic DNA from patients of this study was 
mainly used for the detection of existing genetic variants by sequencing as well as for 
subcloning, generating gene promoter reporter vectors. The Münster MolProMD Study is a 
prospective study of patients with CVD (MI, essential hypertension) and families, aimed at 
studying molecular genetic mechanism of CVD. The study was approved by the ethics 
committee of the Medical Faculty, Westphalian Wilhelms-University of Münster and written 
informed consent was obtained from all study subjects. 
 
3.5 Computational sequence analyses 
Web based algorithms were used for in silico DNA sequence analyses. For phylogenetic and 
gene family footprinting, sequences were aligned using the ClustalW program at EMBL 
(http://www.ebi.ac.uk/Tools/clustalw/index.html). For prediction of TF binding sites, DNA 
sequences were compared to the TRANSFAC 7.0 database by using AliBaba2.1 
(http://www.gene-regulation.com/pub/programs/alibaba2/index.html) and PROMO 
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3). PROMO 
(accessing TRANSFAC 8.3) was also used to analyse regulatory sequences of different genes 
expressed in the same tissue using the MultiSearch site function and for phylogenetic 
footprinting with comparison of TF binding sites. Furthermore, PROMO was used for 
consensus sequence identification and matrix visualization to design oligos with defined TF 
binding qualities serving as controls in EMSA experiments. Settings of the used algorithms 
are available upon request (Chenna et al., 2003; Grabe, 2002; Messeguer et al., 2002). 
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4 RESULTS 
 
4.1 Phylogenetic footprinting 
 
To reveal nucleotides under evolutionary selection in the BGN 5'-flanking region and 5'-UTR, 
phylogenetic footprinting was performed by comparison of human (Acc#: NT_167198.1) and 
mouse (Acc#: NT_039706.7) sequences using ClustalW at http://www.ebi.ac.uk. 
Evolutionary conservation of sequences over longer time periods is assumed to be the result 
of negative selection, implying identical function and expression of the compared orthologous 
genes (Tagle et al., 1988). Differential phylogenetic footprinting will potentially be observed 
if a change in expression patterns occurred during the evolutionary process (Fischer & 
Backendorf, 2007). Results obtained by this method depend considerably on the species used 
for comparison. Sequences from species with small evolutionary distances may well not 
reveal enough mutations outside of cis-elements whereas species which are evolutionary more 
distant will not reveal any residual homology. Phylogenetic footprinting may furthermore not 
be used unrestrictedly to identify regions containing cis-active elements. Since the structure of 
the genome is highly variable between organisms and control regions may well be localized in 
intronic regions, downstream, or in considerable distance of a gene (Trinklein et al., 2007; 
Kleinjan et al., 2005, Lower et al., 2009), control regions are not annotated in databases and 
may be tracked only by their flanking gens. Different arrangements of genes (i.e. copy 
number, orientation) in different organisms introduce considerable uncertainty to this 
procedure. For BGN, sequence homology of ~70% was observed for the 5'-UTR between 
human and mouse, whereas an overall score of ~65% was reported for adjacent upstream 
1150 bp (fig. 10). A notable sequence homology between the two species of ~80% was 
detected between the proximal position -250 and +25 of the human BGN sequence. Sequence 
analyses of the 5'-flanking region using different web-based algorithms (cf. references for 
details) did not reveal a TATA or CAAT box, but multiple GC elements.  
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 mBGN -603 GGGGGTGGGGGGCAAATGCCTCGTTTTAAAGGAGGAAAGGAAGGAGAAGAGGAAAGGCTA  
 hBGN -599 CTTTTTAAGGGAAGAAAGTCTGGAGTGGAAGGGAGGGCACAGGGCGCCAGGAGCCTACAT  
 
 mBGN -543 ACAGAGCCAGTGGGATCCTGGATCAAGCCCTTCCAGAAGCCTACC---ATCCTCTACATC  
 hBGN -539 GAAGTCCTTCCAGAAATCCACAACAGCTACCTCTCTGATCCTGGAGAAACCACCTCCTTG  
 
 mBGN -486 TATAATCCCCAAAGTGCCCCTGGC---TTCAGACTTAAGTTCTGGG--------------  
 hBGN -479 CTTAGGCCCAAGCAGGTTCCTGGCAGGCTCAGGACCAAATTCCAGGGGCCACTCATGGGC  
  
 mBGN -443 -TAGCCATC--AGGTTACCTTTCC-TCATCTTCCTCTCA-----CTTTCTTCTGCCTAGC  
 hBGN -419 CTAGCAGCCCAAGGCCGCCTCCCCCTCGTCTTTCTTCCATCTCTCTTTCCTCTGCCTGGC  
 
 mBGN -392 CCCACAACAGCAAGCACCTCAGTGTCCCCTTTTGGATAGTGGAAAGTTTGACTCTGTGAG  
 hBGN -359 GAGATGCCAGCCAGCACCTCAGTGTCCCCATCTGGGCAGTGGAAAGTTTGACTCTCTGGG  
  
 mBGN -332 ACTGTCTGCCCAAAGACACCAAGGGTCTGTCCCTAAGTAAGTGAATGTGTGTTCTTTCAA  
 hBGN -299 TC---CTTGTTTGAGTGAGTGCGAGTGTGTCC--------GTTCCTTTGCTGTCTGCC--  
 
 mBGN -272 ACTATGCTTGAGGCAGGGGCCAGGGTGGGGGGCGTGAGGGGGAGGGGTGCCACATAGACC  
 hBGN -252 -CCAGGCGGGGGAGGGGGGGGGAGGTGGTGGGGGCGAGGGGGCGGGGGCTCAGCTAGTCC  
 
 mBGN -212 AGCCGTCTACAAGAAAATTGCTTCCTTTGAAGCTGCCAGGGGGGGCAGGAAGCCTGCCCC  
 hBGN -193 AGCCGTCTACAAGAAAATTGCTCCCTTTGAAGCTGCCAGGGGGGCCGGGAAGCCTGCCCC  
 
 mBGN -152 CTCCCTCCCAGCTGCCCTTCCTCCCCCCTTTTCTCCCTCTCTGCTCCACTAGCCCCCTCC  
 hBGN -133 CTCCTGCTCGCCCGCCCTCTCCGCCCCACCAGCCCCCTCCCTCCTTT--------CCTCC  
 
 mBGN -92 CTTCTTGTCTCCCTCTCCGCCCCGTCCCCTCCCTGTCGGCCCGCCCGCCCAGCCTTTAGC  
 hBGN -81 CTCCCCG---CCCTCTCCCCGCTGTCCCCTCCCCGTCGGCCCGCCTGCCCAGCCTTTAGC  
  
 mBGN -32 TTCCCTCCCACCGCCTCTGTCTCCCTCTCTCCACGAACTGCCCAGGAGCGAGCAGCTGCT 
 hBGN -24 CTCCCGCCCGCCGCCTCTGTCTCCCTCTCTCCACAAACTGCCCAGGAGTGAGTAGCTGCT  
 
 mBGN +28 CCCGGTTGGCC--------CTGACGGACAGACAAACCGACAGCCTGACAACCTAGTCCAC  
 hBGN +36 TTCGGTCCGCCGGACACACCGGACAGATAGACGTGCGGACGGCCCACCACCCCAGCCCGC  
 
 mBGN +81 CAACTAAGCAGCCTGCACCTGGCTGCTTGTCCCTCCCCAGGAACATTGACC +131 
 hBGN +96 CAACTAGTCAGCCTGCGCCTGGCGCCTC--CCCTCTCCAGGTCCATCCGCC +144 
 
 
Figure 10: Comparison of the mouse and human BGN 5'-flanking region and 5'-UTR.  
Conserved domains are marked in gray. Main human TSS according to DBTSS are indicated by 
arrows. The distal part of the human sequence, position -599 to -230, is not well conserved 
(conservation score ~20%) but holds a highly conserved region of 50 bp at position -352 to -302. The 
proximal part of the 5'-flanking region and the 5'-UTR have an overall conservation of ~80%. 
Alignment was conducted using ClustalW. 
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4.2 Identification of cell lines for BGN promoter studies 
 
For in vitro functional analyses of gene promoters, a cell system expressing the gene of 
interest is mandatory since a defined set of TF accounts for sequence-specific binding of 
accessible cis-active promoter elements and coordinated gene expression control (cf. 1.5). 
Cell lines differ in their TF constitution and selection of a cell system missing on endogenous 
expression can lead to artificial results. Concerning the biological system or pathophysiology 
the gene product is hypothetically involved in, cell lines known to play pivotal roles in these 
processes should be screened routinely. 
 
4.2.1 Endogenous BGN expression analysis 
BGN is known to be expressed ubiquitously throughout the human body but does posses 
different functional properties. It has been shown to be a major component of the ECM and its 
potential as a proinflammatory factor has been reported recently (for details cf. 1.3). We 
therefore analyzed the endogenous expression of BGN in the embryonic kidney cell line 
HEK293T, an African green monkey kidney cell line COS-7, a differentiated vascular 
endothelial cell line EA.hy926 and the monocytic cell line THP-1. Standard transcript 
detection was performed using a SS primer in exon two  
(5'-TGACACCTCGGGCGTCCTGG-3') and an AS primer in exon four  
(5'-GAGCTGGGTAGGTTGGGCGG-3') at 28 cycles in a touchdown PCR with cDNA 
template (amplicon length 348 bp). All cell lines tested positive for BGN endogenous 
expression (fig. 11), in good consent with its ubiquitous expression in vivo. To address 
existing stimulatory aspects in BGN gene expression, cells were incubated with cAMP and the 
phorbol esther PMA. Both compounds elicit broad inflammatory signal transduction 
pathways. cAMP induces the PKA pathway while PMA leads to activation of the PKC signal 
cascade. Stimulation of THP-1 monocytes with PMA (78 hrs) additionally leads to 
differentiation into macrophages. Both stimulatory regimes did not alter the BGN transcript 
level in our experiments (fig. 11). 
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4.2.2 Identification of TSS 
Current databases such as DBTSS (Wakaguri et al., 2008; Ota et al., 2004) hold precise 
positional information on TSS of eukaryotic mRNA, since evolution of high-throughput 
technologies allowed massive sequence analysis of full-length cDNA in the recent past 
(Yamashita et al., 2010). Lately, a continuative refinement has been integrated to take 
differential usages of the TSS, depending on the cellular circumstances, into account. Tags 
were collected from a total of 33 different cell types or culturing conditions. For BGN (Entrez 
gene ID 633) DBTSS reports three main TSS in normal adult tissue (fig. 10). To identify the 
cell type-specific usage of TSS in the human BGN gene promoter, 5'RACE experiments and 
diacritic PCR were used. We were able to show the alternative usage of two TSS (fig. 11) in 
correlation with DBTSS data and termed the identified proximal position TSS1 and the more 
distal position TSS2. The flexible structure of transcription initiation was as well addressed 
with respect to different stimulatory regimes. TSS1 was shown to be actively involved in 
transcription in all tested cell lines independently of the applied stimulation, while parallel 
usage of TSS1 and TSS2 was exclusively detected in EA.hy926 cells. Stimulation of 
EA.hy926 cells with phorbol ester PMA lead to concentration of transcriptional initiation 
upon TSS1 and abrogation of usage of TSS2 (fig. 10). 
We identified four cell lines expressing the human BGN. One of them, the vascular 
endothelial cell line EA.hy926, featuring an alternative TSS (TSS2, fig. 10). Considering the 
dual nature of BGN as a structural protein as well as an inflammatory factor, we decided to 
focus on the EA.hy926 and THP-1 cell lines for further investigations. 
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Figure 11: Analysis of BGN TSS in different cell lines.  
The schematic illustration shows exon one and the upstream 5'-flanking region. Notation of primers 
below is based on the main identified transcription start site, TSS1. Total RNA was used for cDNA 
synthesis followed by semi-quantitative PCR with the indicated 5'-primers and 3'-primer P+623. 
Integrity of cDNA was tested by amplification of hRP27. RNA from human testis tissue served as 
positive control. For stimulation, cells were grown in medium with either 8-bromo-cAMP (0.5 mM) or 
PMA (10-8 M) for 24 hrs. 
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4.3 Characterization of BGN promoter transcriptional activity 
 
For BGN promoter characterization, its transcriptional potential and the identification of 
regulatory sequence regions within, deletion constructs were generated. Since the 5'-flanking 
region of the human BGN gene does not feature a TATA box or other comparable rather 
focused promoter elements to drive its expression, a CpG island sequence analysis (Takai & 
Jones, 2002) was performed to identify regions with potential promoter properties in silico 
(fig. 12). Since the sequence portion of 336 bp predicted to be a potential CpG island spans 
almost completely the 5'-UTR and adjacent ~200 bp of 5'-flanking region, the untranslated 
region of exon one was included in the generated promoter constructs. Serial truncation of 
deletion constructs was planned taking further in silico predictions for TFBS into 
consideration (for details cf. 3.5). Sequence positions with highly conserved TF binding 
clusters were used as markers for each subsequent shortening step of fragments (for schematic 
representation of all deletion constructs and nomenclature see fig. 8). Finally, a fragment 
representing ~1300 bp of the 5'-flanking region with inclusion of the 5'-UTR was selected to 
be analysed in reporter gene assay analyses. 
 
 
 
 
Figure 12: CpG island analysis of the human BGN 5'-flanking region and 5'-UTR. 
We identified one CpG-rich region spanning position -198 to +138 (336 bp), underlined in blue. 
Vertical lines in red mark cytosine/guanine phosphodiesters. Sequence positions are based on TSS1. 
Position -1318 and +162 mark the longest generated promoter deletion construct. The web based 
application CpG Island Searcher (http://www.cpgislands.com) was used with the following settings: 
selected lower limits: %GC=60, ObsCpG/ExpGpG=0.65, length=100, distance=100. 
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4.3.1 Reporter gene assays 
Transient transfection of generated BGN promoter deletion constructs in EA.hy926 cells 
revealed a region with high transcriptional activity in the 5'-flanking region of the gene (fig. 
13). The region between -1231 and -935, covered by three promoter constructs, holds strong 
transcriptional activity reaching the level of pGL3-Control in our experiments. Truncation of 
a 234 bp fragment resulted in a significant (p<0.001) decrease of transcriptional activity. The 
constructs -701/+162 and -386/+162 covering the predicted CpG region of 336 bp (fig. 12) 
hold only limited potential to drive gene expression. Further truncation to a promoter 
fragment representing 39 bp of the 5'-region (-39/+162) but including the 162 bp of the  
5'-UTR, significantly (p<0.05) regenerated promoter transcriptional activity. Notably, the 
promoter construct -1318/+162 did not display any promoter activity at all (RLU beyond 
baseline level). In part restoration of transcriptional activity was achieved by truncation of the 
162 bp 5'-UTR generating the fragment -1318/+1. 
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Figure 13: Transcriptional activity of selected BGN promoter fragments. 
BGN promoter fragments expressing luciferase gene were transiently transfected into EA.hy926 cells 
to identify transcriptionally active regions within the 5'-flanking region. Length of the fragments is 
schematically indicated by filled boxes (left), the 5'-UTR is marked by a shaded box. The positive 
control pGL3-Control (white bar) contains a strong viral promoter and enhancer, the negative control 
pGL3-Basic (black bar) lacks any active promoter. The region between -1231 and -935 holds a strong 
transcriptional activity reaching activity of pGL3-Control, whereas the proximal region starting at 
position -701 exhibits declined transcriptional activity. The fragment spanning -1318 to +162 
including the 5'-UTR (top) shows no transcriptional activity. Excision of the 5'-UTR (bottom) leads to 
partly reconstitution of activity. Levels of significance are shown by asterisk on the right (n.s.: not 
significant, *P<0.05, **P<0.01, ***P<0.001). RLU: Relative Light Units. 
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4.4 Verification of BGN gene variants and MolHaps in the MolProMD study 
To reveal the composition of identified promoter polymorphisms on single DNA strands and 
to define MolHaps, genomic DNA from 57 patients of the MolProMD study were screened. 
One-thousand twenty-five bp of the promoter region harbouring G-578A, G-151A, and 
G+94T were amplified, subcloned, and sequenced twice (both DNA strands with sense and 
antisense primers) using an automated sequencing device. Three MolHaps were verified 
according to previous assumptions: BGN-MolHap1 [G-578-G-151-G+94 (wt)]  
BGN-MolHap2 [G-578-A-151-T+94] and BGN-MolHap3 [A-578-G-151-G+94]. BGN-MolHap1 has 
been designated wt since ancestral allele information was only available for position G-578A, 
with G mutated to A. The variants G-849A and C-501A were not detected in our 57 samples 
from the MolProMD study. 
 
4.4.1 BGN MolHap promoter fragments in reporter gene assays 
Molecular promoter haplotypes have been shown to significantly influence transcriptional 
activity of different genes in reporter gene assays (Hagedorn et al., 2009; Dördelmann et al., 
2008; Hasenkamp et al., 2008). For the analyses of BGN MolHaps, a 1025 bp fragment was 
cloned into pGL3-Basic vector, harbouring either of the three indentified SNP combinations 
(cf. 4.4) and transiently transfected into EA.hy926 and THP-1 cells. Previous analyses in 
HEK293T cells pointed to a higher transcriptional activity of MolHap3 compared to MolHap2 
(Rüssmann, MD thesis) but subsequent EMSA experiments were not sufficiently conclusive 
to reveal the underlying nature of protein/DNA interaction. The analysed promoter fragment, 
spanning position -893 to +132, exerted significant transcriptional activity (~250000 RLU in 
Ea.hy926) comparable to identified fragments with highest transcriptional activity in 
EA.hy926 promoter deletion studies (4.3.1), when wt alleles were present. Introduction of 
MolHap2 and MolHap3 led to a significant reduction of transcriptional activity in EA.hy926 
cells (P<0.001), with total abrogation beyond the level of pGL3-Basic for MolHap3 (P<0.001, 
fig. 14). A consistent result was observed upon transfection in the monocytic cell line THP-1. 
Fragments harbouring variants corresponding to MolHap2 and MolHap3 lead to a significant 
reduction of transcriptional activity (P-values<0.01). The same effects observed under basic 
conditions were also confirmed under the stimulatory regime of cAMP and PMA (not shown).  
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Both compounds did not have any effect on the transcriptional activity of the wt fragment in 
neither EA.hy926 nor THP-1 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Transcriptional activity of BGN MolHaps. 
BGN MolHaps expressing luciferase gene were transiently transfected into EA.hy926 (left) and THP-1 
cells (right) to identify the influence of SNP combinations on transcriptional activity. The wt fragment, 
representing BGN-MolHap1 [G-578-G-151-G+94 (wt)],  exhibited significant transcriptional activity in 
both cell lines. Transcriptional activity of BGN-MolHap2 [G-578-A-151-T+94 (H2)] was significantly 
reduced, whereas introduction of BGN-MolHap3 [A-578-G-151-G+94 (H3)] led to total abrogation of 
transcriptional activity in EA.hy926 cells and further reduction in THP-1 cells. The positive control 
pGL3-Control (white bar) contains a strong viral promoter and enhancer, the shuttle control 
pGL3-Basic (black bar) lacks any active promoter. Levels of significance are shown by asterisk 
(*P<0.05, **P<0.01, ***P<0.001). RLU: Relative Light Units. 
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4.4.2 Analysis of BGN promoter SNPs in transfection experiments 
For in-depth characterization of each genetic variant in the context of its narrowed promoter 
region, fragments containing each variant with minimal surrounding sequence portions cloned 
into the pGL3-Promoter vector (kind gift of Christina Rüssmann) were used. This vector of 
the pGL3-System, which contains an SV40 promoter, was initially generated to analyse 
isolated promoter portions towards their potential as individual enhancer elements. The six 
vectors contained either allele at position G-578A in a 187 bp fragment, the alleles at position  
G-151A in a 188 bp fragment and alleles at position G+94T in a 158 bp fragment. The 
generated vectors were transiently transfected into EA.hy926 cells (fig. 15). Position G-578A 
was able to slightly enhance activity of the pGL3-Promoter vector. A mild enhancing effect 
was also observed for -151A, whereas the wt allele -151G reduced transcriptional activity 
below empty pGL3-Promoter vector activity. Neither allele present at position G+94T did 
exert any enhancing activity in the present transfection experiments (all P-values <0.01). 
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Figure 15: Transient transfection of BGN promoter fragments harbouring insulated variants. 
Isolated variants were transiently transfected into EA.hy926 cells. Both alleles at position G+94T 
reduced basic transcriptional activity of the pGL3-Promoter vector. Introduction of the A allele at 
position G-151A and both alleles at position G-578A enhanced transcriptional activity of  
pGL3-Promoter. The positive control pGL3-Control (white bar) contains a strong viral promoter and 
enhancer, the shuttle control pGL3-Promoter (black bar) contains an SV40 promoter without enhancer. 
Levels of significance are shown by asterisk (**P<0.01, ***P<0.001). RLU: Relative Light Units. 
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4.4.3 In silico analysis of BGN promoter regions  
An extensive in silico analysis was performed for the characterized BGN promoter region 
(4.3.1) with special respect to alterations in TFBS prediction upon introduction of alleles 
corresponding to BGN-MolHap1-3. A preliminary analysis performed by Rüssmann (MD 
thesis) using AliBaba2.1/TRANSFAC 7.0 revealed, in addition to a few other TF, SP1 TFBS 
for all polymorphic positions.  With SP1 being the most frequent TF overall predicted for the 
entire GC-rich BGN promoter, its predicted binding to the polymorphic regions seemed 
mandatory. To correct for random prediction of TF due to sequence characteristics, the web 
based tool PROMO accessing TRANSFAC 8.3 was used. The tool allows to measure the 
reliability of predictions by using a random sequence of 1000 nucleotides, considering both, a 
model with equiprobability of the four nucleotides and a model with the same nucleotide 
frequency as the query sequence, represented by Query Expectation Values (QEV). The 
results shown in table 7 were obtained using Matrix Dissimilarity Rates (MDR) ≤6% (i.e. 
94% identity to TF consensus sequence). Position G-578A showed binding for the stress-
related protein p53, the B-cell linage-specific activator PAX-5 and a member of the ETS TF 
family (c-Ets1). TFBS prediction for the proximal position G-151A showed condensed 
binding for SP1/SP3 and the B-/T-cell-specific factor LEF-1, with an additional ETS binding 
site. The variant G+94T positioned in the 5'-UTR was predicted to generate a binding site for 
AP-1 TF complex by detection of c-FOS/c-JUN consensus motifs. With AP-1 being not a 
single protein, it constitutes a group of related dimeric basic region-leucine zipper proteins 
that belong to the JUN, FOS, MAF and ATF subfamilies (Shaulian & Karin, 2002). 
 
Table 7: In silico prediction of TFBS. Analyses were performed with sequence input of 60 bp 
contain the identified genetic variants using PROMO accessing database TRANSFAC 8.3.  
-578G -578A -151G -151A +94G +94T 
Name QEV Name QEV Name QEV Name QEV Name QEV Name QEV 
TFIID 0.011 TFIID 0.015 LEF-1 0.000 LEF-1 0.000 HIF-1 0.003 HIF-1 0.003 
c-Ets1 0.020 P53 0.021 c-Ets1 0.002 c-Ets1 0.002 E2F-1 0.003 c-FOS 0.004 
P53 0.022 c-Ets1 0.021 SP1/SP3 0.002 SP1/SP3 0.002 c-FOS 0.004 c-JUN 0.005 
P53 0.031 P53 0.029 NF-E4 0.002 NF-E4 0.002 c-JUN 0.004 CP2 0.010 
Pax-5 0.040 Pax-5 0.037 Pax-4a 0.005 C/EBP-β 0.006 Yi 0.004 NF-1 0.010 
MDR: 6%  
species: human 
MDR: 6%  
species: human 
MDR: 5%  
species: all 
MDR: 5%  
species: all 
MDR: 5%  
species: all 
MDR: 5%  
species: all 
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4.5 Overexpression of TF SP1 
 
In silico TFBS prediction for the BGN promoter in general revealed a number of consensus 
sequences for TF SP1. The TF SP1 is ubiquitously expressed, possesses three C2H2-type zinc 
fingers as DNA-binding domain (DBD) and has two glutamine-rich transactivation domains 
(TAD; Kadonaga et al., 1987; Kadonaga et al. 1988; Courey et al., 1989). Binding was 
predominantly predicted in conserved regions (fig. 10), spanning the proximal positions -230 
to -200 and the region -25 to +5 flanking the main TSS (all matrix dissimilarity rates =0, QEV 
≤0.2). In addition, SP1 binding was predicted for the three identified genetic variants 
composing BGN MolHaps. Based on these findings, we performed co-expression experiments 
in EA.hy926 cells using an expression vector for SP1 (pSP1/CMV). This mammalian 
expression vector is under the control of a promoter-regulatory region of the human 
cytomegalovirus for optimal performance. Effector (pSP1/CMV) to reporter gene vector 
(BGN promoter constructs) ratio was 1:3 in EA.hy926 transient transfections. The empty 
vector pCMV served as shuttle control. Strong induction of BGN promoter transcriptional 
activity in the presence of overexpressed SP1 was observed for all deletion constructs (fig. 17, 
all FI values ≥2.3). Explicitly high FI values over empty shuttle control were observed in 
promoter regions predicted to harbour conserved SP1 TFBS. Fragment -39/+162, including 
the main TSS flanking region and 5'-UTR, featured a 3.5-fold increase in transcriptional 
activity, while fragment -1318/+1 covering the distal part of the promoter and lacking the  
5'-UTR presented a 4.1-fold increase in transcriptional activity. The section between -1231 
and -935, covered by three promoter constructs with highest absolute transcriptional activity, 
displayed a mean induction of transcriptional activity upon SP1 co-transfection by 2.3-fold. 
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Figure 17: Co-expression of TF SP1 and BGN promoter constructs in EA.hy926 cells. 
Significant induction of BGN promoter deletion constructs transcriptional activity was observed upon overexpression of TF SP1. The empty vector pCMV served as 
shuttle control (gray bars, left), corresponding transcriptional activity in presence of overexpressed SP1 is represented by black bars (right). All results reached high 
levels of significance (P ≤0.01). Each constructs‘ relative activity over the empty shuttle vector pGL3-Basic was calculated and expressed as fold induction (FI) on 
the far right. High levels of transcriptional activity induction were observed for fragments -39/+162 (FI by 3.5) and-386/+162 (FI by 2.8) in correspondence with 
SP1 TFBS predictions in these regions. The promoter portion covering positions -1318/+1 (no 5'-UTR) reached the highest level of FI (by 4.1). Levels of 
significance are shown by asterisk (**P<0.01, ***P<0.001). RLU: Relative Light Units. pGL3-Control is represented by white bars. 
+ pCMV
0 100000 200000 300000 400000 500000200000 50000 0 0 400000 500000300000200000100000
-1318/+1
-1231/+162
-935/+162
-701/+162
-386/+162
-39/+162
pGL3_ctrl
pGL3_bsc
1098/+162
+ pSP1
***
***
***
***
**
***
***
FI
4.1
2.0
2.7
2.3
2.4
2.8
3.5
1.0
RLU RLU
4 Results 
page | 69  
 
 
4.6 ChIP experiments 
 
Since overexpression of TF SP1 resulted in strong induction of BGN promoter transcriptional 
activity, ChIP experiments were performed for in vivo verification of these results. 
Stimulation of BGN transcriptional activity might not originate from direct binding of SP1 to 
the promoter itself, but could exert indirect regulatory effects. Demonstration of SP1 binding 
to the BGN 5'-flanking region in ChIP experiments would verify direct physical interaction of 
SP1 with the BGN promoter. 
Proteins interacting with chromatin were chemically cross-linked using formaldehyde 
followed by sonification of DNA. Precipitation of bound promoter segments was achieved by 
the use of selected specific antibodies against SP1, GATA1 and phosphorylated CREB. Three 
distinct regions of the BGN promoter were amplified in PCR reactions following ChIP, with 
mean amplicon length of 100 bp. Neither binding of GATA1 nor binding of CREB was 
detected at any of the analysed sections, while binding of SP1 was demonstrated for region  
-28 to +71 and -918 to -806 (fig. 18). ChIP results were in correspondence with co-expression 
experiments since the region flanking the main TSS and the more distal parts showed strong 
induction of transcriptional activity upon SP1 overexpression (fig. 17). The promoter portion 
spanning -1164 to -1066 did not show binding of TF SP1 in ChIP experiments. 
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Figure 18: TF SP1 interacts selectively with 
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4.6.1 ChIP analysis of BGN
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Figure 19: TF SP1 interacts with polymorphic 
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4.7  TGF-β1 signal transduction effects 
 
The multifunctional TGF-β family 
assembly and remodeling. At the
epithelial, endothelial, and haematopoietic cells
this large family with at least 42 members encoded in the human genome, TGF
reported to regulate BGN on transcriptional and posttranscriptional levels 
2006; Tiede et al., 2010) and thereby influence its availability and protein characteristics
(Little et al., 2008). Most of the currently available data has however come from studies
concentrating on the role of proteoglycans in fibrotic processes, using fibroblast cell lines. 
Since cytokines from the TGF
versatility, a detailed analysis of 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: TGF-β1 stimulates BGN
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Semi-quantitative PCR analysis of BGN mRNA levels upon TGF-β1 stimulation revealed an 
activating effect in THP-1 monocytes, while EA.hy926 cells did not respond to the cytokine 
(fig. 20). To execute its intracellular signal transduction capacity, TGF-β1 needs to activate 
either one of two transmembrane serine/threonine receptor kinases. The type II receptor 
(TGFBR2) is required for the antiproliferative activity of TGF-β, whereas the type I receptor 
(TGFBR1) mediates the induction of several genes involved in cell-matrix interactions (Ebner 
et al., 1993). Expression of TGFBR1 is therefore essential for downstream regulatory effects 
of TGF-β1 on BGN gene expression. We tested both cell lines, THP-1 and E.hy926, using 
semi-quantitative PCR and verified the presence of TGFBR1 mRNA (not shown). We further 
analysed the downstream effects of TGF-β1 on the level of transcriptional promoter 
activation, since variations in BGN mRNA levels could depend on post-transcriptional RNA 
modification. Transient transfection of BGN promoter deletions constructs under the 
stimulatory regime of TGF-β1 (fig. 21) revealed inducibility of transcriptional activity in 
THP-1 cells in correspondence with diagnostic PCR results (fig. 20). Significant changes in 
transcriptional activity over pGL3-Basic compared to basic conditions were observed in 
fragments representing region -1231 to -935, displaying highest transcriptional activity in 
THP-1 cells. Overall FI observed was 2.6. In analogy to BGN mRNA levels, no stimulatory 
effect of TGF-β1 on transcriptional activity of any promoter fragment was observed in 
EA.hy926 cells (fig. 22).  
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Figure 21: TGF-β1 induces transcriptional activity 
Transcriptional activity of BGN promoter fragments was induced up to 3
fragments spanning the region -1231 to -935. Basic conditions are shown on the left (gray bars), corresponding 
represented by black bars (right). Each constructs‘ relative activity over the empty shuttle vector pGL3
the far right. Levels of significance are shown by asterisk 
  
 
 
basic conditions 
-1231/+162 
-1098/+162 
-935/+162 
pGL3_bsc 
pGL3_ctrl 
THP-1 
of the BGN promoter in THP-1 cells. 
-fold upon stimulation with TGF-β1 (10 ng/ml, 24 hrs)
transcriptional activity
-Basic was calculated and expressed as fold induction (FI) on 
(*P<0.05, **P<0.01). RLU: Relative Light Units. pGL3-Control is represented by white bars.
TGF-β1 
page | 74  
 
. The effect was most prominent for 
 in presence of TGF-β1 is 
 
4 Results 
page | 75  
 
basic conditions  
TGF-β1 
pG
L3
_
ctr
l
pG
L3
_
ba
sic
-
13
18
/+1
62
-
13
18
/+1
-
12
31
/+1
62
-
10
98
/+1
62
-
93
5/+
16
2
-
70
1/+
16
2
-
38
6/+
16
2
-
39
/+1
62
0
30000
60000
100 000
800 000
pG
L3
_
ctr
l
pG
L3
_
ba
sic
-
13
18
/+1
62
-
13
18
/+1
-
12
31
/+1
62
-
10
98
/+1
62
-
93
5/+
16
2
-
70
1/+
16
2
-
38
6/+
16
2
-
39
/+1
62
0
30000
60000
100 000
800 000
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: TGF-β1 does not affect BGN transcriptional activity in EA.hy926 cells.  
Transcriptional activity of BGN promoter fragments was not altered upon stimulation with TGF-β1 
(10 ng/ml, 24 hrs). Basic conditions are shown on top, corresponding transcriptional activity in 
presence of TGF-β1 below. RLU: Relative Light Units. pGL3-Control is represented by white bars. 
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Figure 23: TF SP1 is decreased by TGF
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4.8 Band shift experiments 
Gel shift experiments were used to access binding of TF with defined BGN promoter regions 
in vitro. Biotinylated probes generated resembled the flanking regions of the three genetic 
variants which constitute BGN MolHaps. All probes were between 31 and 36 bp in size, 
limiting potential binding partners to the exact polymorphic region. Since BGN MolHaps span 
a region of 672 bp, combined analyses in EMSA experiments were inexecutable. To visualize 
sequence-specific binding, unlabelled probes in a 200-fold excess were used in any gel shift 
for signal competition. For identification of proteins binding at positions of observed gel 
shifts, specific antibodies were used according to in silico TF binding predictions. 
 
4.8.1 EMSA at position G+94T 
Position G+94T has been shown to influence transcriptional activity of the BGN promoter 
significantly in transient transfection experiments (4.4.1). Introduction of the T resulted in 
strong abrogation of reporter gene plasmid transcriptional activity. Using biotinylated probes 
resembling the flanking sequence of position G+94T with EA.hy926 and THP-1 nuclear 
extracts, we observed considerable differences in DNA/protein binding patterns (fig. 24). For 
both cell lines, a prominent and sequence-specific band shift (black arrow) was detected with 
significant higher binding affinity to the probe bearing the +94T allele. Of lower intensity, a 
second specific shift (open arrow) emerged.  
Using in silico methods (tab. 7), AP-1 was predicted to be a potential binding partner for 
position G+94T. AP-1 is known to directly affect gene transcription and is individually 
composed of multimeric TF, often including a heterodimer of the basic leucine zipper proteins 
c-FOS and c-JUN (Shaulian & Karin, 2002). Regulatory properties of AP-1 are versatile. Of 
all components, the most potent transcriptional activator is c-JUN, whose transcriptional 
activity can be antagonized by JUNB. FOS proteins enhance JUN DNA-binding activity upon 
formation of stable heterodimers. Gel shifts with unlabelled probes harbouring the +94 G or T 
allele and EA.hy926 nuclear extracts were detected using a c-FOS specific antibody to 
demonstrate AP-1 complex formation at this position (fig. 25). An AP-1 consensus sequence 
served as positive control (Kodonaga et al., 1987). We detected a strong c-FOS signal when 
the AP-1 oligonucleotide was used, demonstrating potential complex formation under applied 
EMSA conditions. By use of this positive control, binding of c-FOS to both alleles, G and T  
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at position +94 was demonstrated (open arrow). The band shift (fig. 25, open arrow) 
identified to involve c-FOS does not exhibit differences in signal intensity in consent with the 
results obtained using c-FOS antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Allele-specific interaction of nuclear extracts with position G+94T.  
Nuclear extracts from EA.hy926 and THP-1 cells bind explicitly to the +94T allele, while only minor 
interaction with the +94G allele was observed (black arrow). A less prominent but specific shift is 
marked by an open arrow. -: 3'-biotinylated probe; +: 200-fold excess (8 pmol) of sequence-specific 
competitor. Unbound oligonucleotides are visible at the bottom (free probe). 
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Figure 25: TF c-FOS binds to position G+94T in EA.hy926 cells. 
Using a c-FOS-specific antibody, one of the observed shifts (cf. fig. 24, open arrow) was identified to 
involve binding of TF c-FOS. A consensus site for TF complex AP-1 served as positive control.  
Ø: lanes without any oligonucleotide served as control for unbound protein separation in native gels. 
All oligonucleotides were used at a concentration of 8 pmol. 
 
 
 
4.8.2 EMSA at position G-151A 
Gel shift experiments with biotinylated probes resembling position G-151A and EA.hy926 
nuclear extracts revealed two specific bands for both alleles (fig. 26, A). A different 
separation of band shifts was observed using nuclear extracts from THP-1 cells, while bands 
were also specific but no differences between alleles was observed (fig. 26). ChIP analysis of 
this position (cf. fig. 19) revealed binding of TF SP1 in EA.hy926 cells. Genotype of 
EA.hy926 cells was determined by sequencing to represent BGN MolHap1, harbouring the G 
allele at position -151. EMSA experiments were used to verify these results and to further 
access binding of SP1 to the A allele. Taking in silico predictions (tab. 7) for position  
G-151A and consensus site weight matrix information into account, a mutated probe was 
designed by altering either two nucleotides at both ends of the probe basic for TF SP1  
EA.hy926 
Ø G
 
T
 
AP-1
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binding. Application of the altered oligonucleotide as specific competitor did not resulted in 
competition and signal intensity of both probes representing either G and A allele did not 
changed (fig. 26, B). Use of the mutated sequence as biotinylated probe itself featured a 
completely different binding pattern. The most considerable and strongest signal (black 
arrow) was undetectable in lanes using the mutated probe. To directly identify the presence of 
SP1 in this DNA/protein complex, a SP1-specific antibody was used for signal detection. This 
approach revealed binding of TF SP1 to both alleles at position G-151A with identical signal 
intensity. As designed, the oligonucleotide missing perfect SP1 consensus sites did not bind to 
the TF.  
We further investigated whether SP1 binding was of stoichiometric nature, or binding was 
linear to probe concentration. Application of the unlabeled -151G probe in different 
concentrations (fig. 27) resulted in consequent increase of signal intensity linear to amount of 
available oligonucleotide. Level of saturation was reached at a concentration of 4.0 pmol. 
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Figure 26: Sequence-specific binding of SP1 
A: Nuclear extracts from EA.hy926 
B: The mutated sequence M (depicted
binding of the unaltered sequence. Using the mutated sequence as 
different binding pattern. The band indicated by a black arrow was identified to bind SP1 by 
SP1 antibody (far right). The mutated probe does not show any residual binding of SP1.
 -: 3'-biotinylated probe; +: 200-fold excess
any oligonucleotide served as control for unbound protein separation in native gels. 
oligonucleotides are visible at the bottom (free probe).
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Figure 27: Binding of SP1 in -151G probe serial dilution. 
TF SP1 binds the unlabelled -151G probe in relation to oligonucleotide quantity. Saturation of binding 
was reached at a probe concentration of 4.0 pmol using EA.hy926 nuclear extracts. Ø: lane without 
any oligonucleotide served as control for unbound protein separation in native gels. 
 
 
 
4.8.2.1 THP-1 band shift experiments 
Gel shift experiments using THP-1 nuclear extracts featured a different binding pattern 
compared to nuclear extracts derived from EA.hy926, missing the most prominent signal (fig. 
26, black arrow) representing SP1 interaction. Two specific interactions were observed (fig. 
28, arrows) but gel shifts did not differ in dependency of the present allele. Using a SP1 
consensus site as sequence-specific competitor did not result in signal intensity decrease and 
application of the mutated probe (cf. fig. 26) showed identical binding compared with 
unaltered probe sequences. 
SP1 
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Figure 28: Sequence-specific interaction of THP-1 nuclear extract with G-151A is independent 
of TF SP1.  
Left: THP-1 nuclear extracts specifically bound to position G-151A (arrows). Centre: Incomplete 
competition of bands was observed using SP1 consensus sequences. Right: The mutated probe M (fig. 
26) shows identical specific binding pattern. -: 3'-biotinylated probe; +: 200-fold excess (8 pmol) of 
sequence-specific competitor. SP1: A SP1 consensus site served as specific competitor. Unbound 
oligonucleotides are visible at the bottom (free probe). 
G A 
- - SP1 SP1 
G A 
- - + + 
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- + 
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4.8.3 EMSA at position G-578A 
Band shift analysis of position G-578A using EA.hy926 nuclear extracts revealed a prominent 
allele-specific effect for probes harbouring the G allele (fig. 29 left, black arrow), while no 
specific effect was observed for position -578A. Application of nuclear extracts obtained from 
TGF-β1 stimulated cells changed the observed DNA/protein bands, resulting in amplification 
of a second shift (open arrow) with higher signal intensity for the A allele and abrogation of 
the interaction with the G allele (black arrow). Signal detection using SP1-specific antibody 
did not reveal any interaction of unstimulated nuclear extracts with SP1 (fig. 29, right), while 
a positive result was obtained for protein extracts from TGF-β1 treated cells. Binding of TF 
SP1 is observed in parallel to gel shift intensification (open arrow) upon TGF-β1 stimulation. 
Nuclear extracts from THP-1 cells presented a different binding pattern, with one 
considerable specific band (fig. 30, black arrow). Upon application of TGF-β1 stimulated 
nuclear extracts, an additional shift occurred for THP-1 cells (fig. 30, angled arrows). In 
consistence with results observed using stimulated EA.hy926 extracts, the emerging 
DNA/protein interaction was identified to depend on SP1 binding. 
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Figure 29: TGF-β1 stimulation alters interaction of EA.hy926 nuclear extracts with position  
G-578A. 
An allele-specific gel shift (black arrow) was detected for the -578G allele using nuclear extracts from 
cells held under basic conditions (left). TGF-β1 stimulated extracts show differential binding pattern 
with an emerging band at the top of the gel (open arrow). The emerging band was identified to depend 
on SP1 binding to the probes (far right). -: 3'-biotinylated probe; +: 200-fold excess (8 pmol) of 
sequence-specific competitor. Unbound oligonucleotides are visible at the bottom (free probe). Ø: lane 
without any oligonucleotide served as control for unbound protein separation in native gels. 
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Figure 30: TGF-β1 stimulation enhances SP1 binding to position G-578A in THP-1 cells. 
A specific gel shift (black arrow) was detected for the G-578A position allele using nuclear extracts 
from cells held under basic conditions (left). TGF-β1 stimulated extracts show differential binding 
pattern with an emerging band (angled arrows). The emerging band was identified to depend on SP1 
binding to the probes (far right). -: 3'-biotinylated probe; +: 200-fold excess (8 pmol) of  
sequence-specific competitor. Unbound oligonucleotides are visible at the bottom (free probe). Ø: lane 
without any oligonucleotide served as control for unbound protein separation in native gels. 
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We further investigated in silico binding predictions for both alleles with special respect 
towards cell-specific regulatory factors. Computational analysis revealed an altered PU.1  
consensus site upon introduction of the A allele at position -578. The hematopoietic  
ETS-domain transcription factor PU.1 has been identified to regulate human 
monocyte/macrophage differentiation (Rosa et al., 2007) and could account for cell-specific 
BGN gene expression. The sequence-specific gel shifts observed using nuclear extracts from 
untreated and TGF-β1 stimulated THP-1 cells (fig. 30, black arrow) were detected using 
specific PU.1 antibody (fig. 31). Binding of PU.1 was identified to probes harbouring either 
one allele with increased binding of PU.1 when stimulated protein extracts were applied. 
Potential differences in binding affinity were assessed using probe serial dilution (fig. 32). A 
4-fold higher binding affinity of PU.1 towards the probe harbouring the -578G allele 
compared with the probe presenting the A allele was observed in these experiments, in 
agreement with previous in silico analyses. 
 
 
 
 
 
 
 
 
 
Figure 31: TF PU.1 binds position G-578A in THP-1 cells. 
TF PU.1 binds unlabelled -578 probes independent of the present allele. Binding is increased in 
nuclear extracts from TGF-β1 stimulated cells. Ø: lane without any oligonucleotide served as control 
for unbound protein separation in native gels. 
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Figure 32: TF PU.1 binds the G allele with higher affinity. 
TF PU.1 binds unlabelled -578 probes in relation to oligonucleotide quantity. Signal intensity of the 
probe bearing the G allele detected by specific PU.1 antibody was increased 4-fold compared to probe 
-578 harbouring the A allele. Ø: lane without any oligonucleotide served as control for unbound 
protein separation in native gels. 
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5 DISCUSSION 
 
In the present work we analysed the transcriptional regulation of the human BGN gene 
expression. We have put our emphasis on the impact of genetic variants G-578A 
(rs11796997), G-151A (Brand et al., 2002) and G+94T (rs5945197) within potential  
cis-regulatory regions, i.e. potential TF binding sites. To our knowledge only a view 
publications (Ungefroren & Krull, 1996; Heegaard et al. 2004) aimed at characterizing the 
molecular basis of BGN transcriptional regulation and little is known about its polymorphic 
promoter structure and consequences for its regulation. We identified a promoter portion of 
1025 bp exerting sufficient transcriptional activity in EA.hy926 and THP-1 cells. In the 
context of this 1025 bp construct, we observed a prominent effect of SNPs (G-578A, G-151A 
and G+94T) reducing BGN promoter transcriptional activity. By generation of truncated 
promoter constructs, co-expression experiments and detailed band shift analyses, we 
identified c-FOS and SP1 to up-regulate BGN gene expression. Moreover, haematopoietic TF 
PU.1 significantly up-regulated monocyte-specific BGN promoter activity. 
 
5.1 Variable TSS of the BGN gene 
 
Transcription of the BGN gene is documented to initiate from multiple TSS (Ungefroren & 
Krull, 1996; DBTSS) and results in varying lengths of transcripts’ 5'-UTR. In this study, we 
used the 5'RACE approach to analyse the transcriptional organization of the BGN promoter. 
This led to the identification of a TSS (TSS1) three bp upstream of a major TSS (AK092954) 
listed in DBTSS, which was detected by oligo-capped cDNA analysis. In the endothelial cell 
line EA.hy926, we further identified a TSS located 46 bp upstream of TSS1. This second TSS 
is used in parallel to TSS1, resulting in two diverse BGN transcripts, simultaneously 
expressed under basic conditions as well as under protein kinase A pathway stimulation with 
cAMP. Using the phorbol ester PMA, initiation of transcription was preferred from TSS1. In 
contrast to other reports (Ungefroren & Krull, 1996), no further upstream TSS existed in our 
tested cell lines. Detection of varying TSS in close vicinity, as observed in our experiments 
for TSS1, has been discussed with regard to technical inaccuracy of applied methods 
(Hagedorn et al., 2009). This has been particularly proven for primer extension of cDNA 
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products using radiolabelled primers, where excessive radiation may result in degradation of 
5'-ends and mis-determination of TSS. 5'RACE methodology, which includes primer 
extension enhanced by PCR amplification and allows determination of the 5'-end of lower 
abundant transcripts produced from weaker promoters (Scotto-Lavino et al., 2006), has been 
proven to identify TSS more accurately.  
The distribution of the TSS could reflect the dynamic nature of the transcriptional initiation 
events, labelling them as regions with TSS in close proximity rather than static positions. This 
flexible structure of transcript initiation has explicitly been reported for CpG island promoters 
(Smale & Kadonaga, 2003). Although multiple TSS are present, broad-type promoters still 
display a preference for specific initiation sites (Carninci et al., 2006). Our results as well as 
findings from other groups (Wegrowski et al., 1995; Ungefroren & Krull, 1996) suggest a 
broad TSS distribution over the BGN promoter. Using multiple TSS over an extended region 
thereby requires exclusion of ATG start codons from sequences downstream of initiation sites 
since translation generally starts from the first ATG in the nascent mRNA (Lee et al., 2005a). 
Interestingly, general ATG distribution within the human BGN 5'-flanking region is adjourned 
362 bp upstream of TSS1, generating a so called ATG desert. The intention of multiple 
promoter TSS usage, specifically for the major group of CpG island promoters in mammals, 
is still under investigation. Of importance, these findings imply that we cannot consider the  
5'-end of the longest cDNA of a gene as the true full-length transcript. There is evidence that 
TNFIID complex formation actually occurs relatively non-specifically and scans along the 
DNA for a TSS (Sandelin et al., 2007). This will allow for parallel assembly of PIC in 
presence of multiple TSS and could regulate transcript initiation and gene expression. In our 
work, the observed concentration of transcript initiation on TSS1 after stimulation with PMA 
did nevertheless not translate in reduction of total BGN transcript level. Altered mRNA  
5'-regions could also result in modified mRNA half-life but mRNA is stabilized by intron size 
rather than destabilized by the lack of exonic regions (Ross, 1995). Posttranscriptional effects 
of altered mRNA 5'-cap thus may play a role for BGN translational processes. After release 
from the nuclear pore, mRNAs are often directed to particular sites in the cytoplasm, driving 
subcellular protein localization patterns (Lécuyer et al., 2007).  
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5.2 BGN promoter capacity is altered by genetic variants 
 
The impact of genetic variants residing within or near cis-active elements on promoter 
activity has been reported repeatedly by our group and others (Dördelmann et al., 2008; 
Hagedorn et al. 2009; Telgmann et al., 2008; Funke-Kaiser et al., 2003; Frisdahl et al., 2005; 
Schultz et al., 2009). Transient transfection assays in cell lines expressing the gene of interest 
are state of the art for in vitro determination of effects on promoter transcriptional activity, but 
certain conditions are necessary for their quantification. The analysed deletion construct, 
resembling the promoter portion carrying a certain allele, needs to display sufficient 
transcriptional activity. Therefore, assembly of the basic transcription machinery and 
formation of PIC on the analysed fragment is mandatory since specific transcriptional activity 
is defined by differential interplay of cis-active elements with the core promoter (Lemon & 
Tjian, 2000). To translate into measurable reporter gene expression, a downstream TSS is 
necessary. Reliable results also depend on transfection efficiency and technical accuracy 
indicated by low standard deviations across experiments. Genetic variants in a given promoter 
fragment may contribute differentially to overall transcriptional activity of the analysed 
fragment since sequence alterations can influence core promoter motives such as TATA 
boxes (as shown for RhoA by Schröer, Ph.D. thesis) and recognition of consensus sequences 
by TF at cis-elements. Combinations of alleles on the same DNA strand, represented by 
MolHaps are thereby often observed to result in overall differential effects on transcriptional 
activity, acting synergistically or competitively (Dördelmann et al., 2008; Hagedorn et al., 
2009). A preliminary analysis of ~200 bp isolated promoter portions harbouring BGN variants 
in the context of the pGL3-Promoter vector (Rüssmann, MD thesis) suggested limited 
enhancer capacity of the single fragments upon transfection into HEK293T cells. The results 
suggested the necessity to further characterize the ‘entire’ BGN promoter and to analyse the 
genetic variants in their original MolHap composition. Despite the endogenous BGN 
expression of HEK293T cells, the composition of HEK293T nuclear proteins (i.e. DNA 
binding proteins) seemed to interact indifferently with BGN MolHaps, lacking the potential 
do drive BGN transcriptional activity with respect to the individual BGN promoter 
composition. This was also supported by the observations obtained from EMSA experiments 
with HEK293T nuclear extracts for positions G-578A and G-151A. Band shift experiments of 
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multiple compositions repeatedly failed to exhibit specific DNA/protein interactions. 
EA.hy926 and THP-1 cells were therefore chosen for the current BGN promoter analysis, in 
addition to their close connection with atherosclerosis pathophysiology. 
 
In the present characterization of the BGN promoter, we report sufficient transcriptional 
activity of deletion constructs presenting the region between bp -1231 to -935. The promoter 
was sufficiently transcriptionally active under basal conditions in the vascular endothelial cell 
line EA.hy926. The vascular endothelium lines all blood vessels in a luminal monolayer and 
forms, together with the basal membrane, the tunica intima. The basal membrane thereby 
consists of a specialized ECM (Wiradjaja et al., 2010), its composition being influenced by 
the endothelial cell phenotype, connecting the endothelium to vascular smooth muscle cells. 
During development of collagen matrices initial fibrils are cross-linked by SLRP such as 
BGN, binding to different sites of a collagen monomer (for comprehensive review see 
Kalamajski & Oldberg, 2010). Hence, sufficient transcriptional activity of the BGN gene 
under basic conditions seems conceivable since assembly of the ECM is a permanent process. 
Potential effects of the identified MolHaps were analyzed within the context of a 1025 bp 
portion of the BGN promoter (-893/+132) after in-depth analysis of 1300 bp 5'-flanking 
region and 5'-UTR of the BGN gene. We are aware that the analysed portion may not be 
considered as the entire promoter since recent publications have shown the profound effect of 
cis-acting elements located at considerable (up to 1000 kb) distances (Lower et al., 2009, 
Higgs et al., 2008). On the other hand, distal promoter elements acting independently of their 
location have been described to consist of enhancers and insulators influencing the activation 
of high-level transcription rather than basic promoter activity (West & Fraser, 2005). BGN 
MolHap2 and MolHap3 showed a significant decrease of promoter performance in both, 
EA.hy926 and THP-1 cells under basic conditions compared to wt. To verify our hypothesis 
of concerted interaction of TF binding to polymorphic regions in haplotype constellations 
with their core promoter, we tested each variable region with potential enhancer activity in the 
context of the pGL3-Promoter vector. The vector contains a SV40 promoter and introduced 
DNA fragments potentiate luciferase gene activity in case they exert enhancer capacity. BGN 
promoter fragments proximal to TSS1 at positions G-151A and G+94T did not enhance 
promoter activity when the major allele was present. For the minor +94T allele carrying 
construct, we observed total inhibition of promoter activity, while introduction of the minor  
-151A allele in the context of 188 bp flanking region activated transcriptional activity to some 
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extent. The more distal promoter portion harbouring G-578A exerted enhancer capacity in 
interaction with the SV40 promoter. These results implicate an overall compensatory effect of 
the analysed polymorphic positions in their allelic MolHap constellations, demonstrated 
explicitly by positions G-578A (MolHap1 and 3) and G-151A (MolHap1 and 2). Presence of 
the minor alleles in the MolHap situation did not enhance transcriptional activity but resulted 
in strong abrogation of activity. However, single variant analysis in context of the  
pGL3-Promoter revealed differences between the introduced alleles and their effect on 
transcriptional activity, suggesting alterations in consensus motives and TF binding. 
 
 
5.3 Identification of DNA/protein interactions  
 
At the molecular level, gene expression is orchestrated by the recruitment of trans-acting 
proteins (TF) to cis-acting sequences (binding sites), creating a series of cis-regulatory 
modules (CRM) along a given sequence. CRM act as modular units, integrating the input  
from multiple TF to a specific spatio-temporal output of gene expression. Binding of TF 
thereby depends on electrostatic interaction with the DNA molecule at TFBS, as well as the 
stoichiometric availability of the TF participating in module assembly. Overlapping or 
superimposed binding sites for multiple factors may thereby result in binding competition of 
diverse regulatory proteins (Fry & Farnham, 1999), some of them contributing differently to 
overall transcriptional activity. TFBS exhibit specific characteristics with each nucleotide 
accounting differentially to the molecular function of the entire site. The relevance of each 
nucleotide is commonly illustrated by a position weight matrix (Piipari et al., 2010), also used 
for computational prediction of TFBS.  
Modification of TFBS by genetic variants may result in a complete loss of TF binding but 
alteration of binding affinity is more likely to be observed since consensus sequences are 
multivalent. Computational TF binding prediction, although integrating position weight 
matrixes, are limited to DNA sequence recognition but cannot account for interactions of 
heteromeric CRM. Comprehensive prediction of protein binding in MolHap constellations 
therefore has not been achieved yet and is in addition suffering from overall missing 
information on the physiological state of a given cell. To account for the stated limitations of 
in silico TFBS prediction, we started our analyses on possible transcriptional regulators of the 
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BGN promoter with co-expression experiments rather than with single position analyses. 
Thereby, TF SP1 was one of the most likely candidates, proposed by different computational 
predictions and the overall GC-rich promoter sequence (Briggs et al., 1986). Additional 
indication were derived from the report of Verrecchia et al. (Verrecchia et al., 2001), 
demonstrating downregulation of BGN and other ECM components as an effect of antisense 
SP1 expression. Here we present substantial evidence for SP1 activation of the BGN promoter 
upon overexpression, enhancing transcriptional activity up to 4-fold. Co-transfection with 
other predicted binding factors such as CEBP-α and δ or CBP did not result in any alteration 
of promoter activity. ChIP analyses of different promoter regions demonstrated direct and 
parallel physical association of SP1 with proximal and distal regions under basic conditions. 
Both results indicated participation of SP1 in the regulation of basal BGN gene expression as 
well as the enhancing nature of SP1, rather than prompting towards indirect downstream SP1 
effects. It has been shown that transcriptional activation by enhancer-binding factors such as 
SP1 requires TFIID (Hoey et al., 1993). SP1 glutamine-rich activation domains thereby 
interact with the TAFII subunits of TFIID and the essential cofactor complex CRSP (Cofactor 
Required for SP1 transcriptional activation; Ryu et al., 1999). Notably, Geerkens and 
colleagues (Geerkens et al., 1995) found that BGN expression levels are increased in patients 
with additional sex chromosomes and suggested the observed ‘pseudo-pseudoautosomal 
expression’ of BGN to result from a gene that escapes X-inactivation and regulates BGN 
transcriptional activity. The gene encoding one domain of the CRSP cofactor complex, 
CRSP150, has been mapped to the X-chromosome. CRSP150 displays pseudoautosomal 
characteristics, escapes inactivation (Wutz & Gribnau, 2007; Carrel et al., 1999) and could 
contribute to this phenomenon. 
 
5.4 BGN MolHaps 
 
In contrast to MolHap3 [A-578-G-151-G+94 ], BGN MolHap2 [G-578-A-151-T+94] comprises two 
minor alleles, one at the proximal position G-151A and one at the 5'-UTR position G+94T. 
The observed reduction of promoter transcriptional activity upon introduction of MolHap2 
could thus originate from altered TF binding at either one of the two positions but is more 
likely to be explained by a deranged interplay of factors interacting with both polymorphic 
promoter segments. 
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We identified binding of the TF complex AP-1 at position G+94T in EMSA experiments 
using a specific c-FOS antibody. AP-1 is known to regulate a wide range of cellular 
processes, including cell proliferation, cell death and differentiation. AP-1 is not a single 
factor, but a combination of dimeric basic leucine zipper proteins that belong to the JUN, 
FOS, MAF and ATF sub-families, which recognize with highest affinity  
12-O-tetradecanoylphorbol-13-acetate (TPA) response elements (5'-TGAG/CTCA-3') and 
slightly lower affinity cAMP response elements (5'-TGACGTCA-3'; Chinenov & Kerppola, 
2001). AP-1 binding may thereby be positioned in the 5'-UTR of a promoter, as reported for 
the sodium-dependent bile acid transporter by Duane and colleagues (Duane et al., 2007).  
The first report on AP-1 described its activation potential on the MTIIA promoter (Lee et al. 
1987a), establishing its name and implicit function as activator of transcriptional activity. In 
recent years, further analyses offered increasing evidence that some effects of AP-1 are 
mediated by gene repression (Murphy et al., 1996). These effects may depend on the 
interactions of AP-1 family members with transcriptional corepressors (Pessah et al., 2000)  
and the nature of the AP-1 consensus site (Hsu et al., 1993). Other groups (Kouzarides & Ziff, 
1988; Gentz et al., 1989; Turner & Tjian, 1989) demonstrated that the leucine zipper domain  
of both c-FOS and c-JUN are necessary for heterodimer formation and transcriptional  
transactivation. The mere presence of a leucine zipper is, however, not sufficient for dimer 
formation. c-FOS does not form homodimers, whereas such a formation has been reported for 
c-JUN complexes with weak AP-1 binding capacity (Dwarki et al., 1990). It therefore seems 
conceivable that detected binding of c-FOS at either allele at position G+94T marks a 
differently composed AP-1 complex with activating capacity in case of the G allele and 
repressor properties in presence of the T allele. Shah et al. (Shah et al., 2006) demonstrated 
transcriptional suppression by AP-1 binding to a polymorphic promoter position (-1347C/T) 
of TGFB1. Cellular studies showed that an AP-1 complex containing JUND and c-FOS was 
recruited to the TGFB1 promoter in vivo only when the -1347C allele was present. The  
-1347T allele was associated with increased TGF-β1 levels because of impaired negative 
regulation by AP-1. Schreiber and colleagues (Schreiber et al., 1999) reported that the p53 
promoter contains a motif that differs from the consensus AP-1-binding site in only one single 
position, creating a negative regulatory element which is bound by c-JUN, resulting in a 
transcriptional repression of the p53 promoter. 
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The transactivating potential of AP-1 has been reported frequently to depend on co-activators 
such as SP1 (Wu et al., 2003; Kardassis et al., 1999). In addition, SP1/SP3 and AP-1 are often 
found as components in large multimeric transcription factor complexes. AP-1 has also been 
reported to fail in transcriptional activity activation upon SP1 inhibition on promoters where 
interaction with SP1 has been observed, suggesting the interaction of AP-1 and SP1 to be 
required occasionally to transmit AP-1 effects (Lee et al., 1987b). The interplay of position 
G+94T and G-151A may therefore be of importance for an overall activating potential on 
transcriptional activity. 
The observed effects at position G-151A have two possible explanations. As a common base 
to both of them, we hypothesize competition of TF with the activating factor SP1 at its 
consensus motif. As explained above, DNA/protein interaction is thought to be a rather 
flexible than static process, with TF tendency towards association or dissociation depending 
to a great extent on the physiological state of the cell. Alteration of cognate sites by genetic 
variation can thereby result in reallocation of balanced conditions. In silico analyses for 
position G-151A predicted a superimposed EGR family consensus motif to the identified SP1 
binding sites. Competition of EGR family members with TF SP1 has been reported 
frequently, in particular for EGR1 (Hagedorn et al., 2009; Hsu et al., 2009; Khachigian et al., 
1995). Both TF share very similar consensus motifs, recognized in either case by three  
zinc-finger DNA-binding domains of the protein. In contrast to SP1, which is an activating 
TF, EGR family members are able to generate repressor characteristics. Except for EGR4, all 
EGR family members exhibit a distinct repression domain (R1), through which binding to 
NAB (NGFI-A binding) proteins can be mediated and the activating potential of EGR is 
suppressed (Russo et al., 1995). This has been shown conclusively by Tan et al. (Tan et al., 
2003) for inhibition of the collagen promoter (COL2A1) by IL1β. In case of BGN, EMSA 
experiments at position G-151A using EGR1 and EGR2 antibodies were inconclusive and did 
not support specific interaction of EGR family members with this distinct promoter segment.  
Yet another explanation for altered transcriptional activity upon TF competition at cis-active 
elements can be found in the SP TF family itself. The ubiquitous TF SP1 and SP3 exhibit very 
similar DNA-binding specificities and compete for binding to the same GC-boxes (Kingsley 
& Winoto, 1992). Therefore, the SP1/SP3 ratio plays an important role in gene regulation (Yu 
et al., 2003). On some promoters, SP3 cooperates with SP1 (Gartel et al., 2000) whereas on 
others, SP3 antagonizes the SP1-mediated activation (Kumar & Butler, 1997). This effect is 
explained as follows. In general, SP3 represses the SP1-mediated transactivation of promoters 
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with two or more SP1 sites but does not affect the SP1-mediated transactivation of promoters 
with only one SP1 site (Ritchie et al., 2000). Moreover, SP3 lacks the ability of SP1 to 
transactivate synergistically via two or more SP1 sites (Majello et al, 1997). Consequently, if 
SP3 displaces SP1 from promoters with at least two SP1 sites, a net repression of the initial 
SP1-mediated transactivation is observed. We have shown binding of SP1 to the BGN 
promoter on at least two distinct positions under basic conditions. Binding of SP3 to the 
promoter, triggered by the G-151A site, would most likely result in the loss of SP1-mediated 
transactivation. Introduction of the minor A allele resembling MolHap2 creates a CT-box 
motif of the 5'-GGGGAGGGGC-3' type. Binding of SP1 to CT-boxes has been reported to be 
sixfold weaker compared to GC-boxes (Letovsky & Dynan, 1989), whereas SP3 binds  
CT-boxes with identical affinity (Hagen et al., 1992).  
In transient transfection assays, we have shown the impact of MolHap3 on BGN 
transcriptional activity, created by introduction of the G-578A site. This observation strongly 
supports the concept of potent alteration of promoter activity by single nucleotide variations.  
In contrast to MolHap2, where interaction of SP1 has been detected at position G-151A, no 
binding of SP1 to position G-578A under basic conditions, neither in EMSA experiments nor 
in ChIP analysis, was observed despite in silico TFBS prediction. Taken the identification of  
SP1 at the nearby position bp -918 to -806 using ChIP technology into account, this result is 
not likely to be explained by methodical inaccuracy but rather provides evidence for ChIP 
assay stringency.  
Using nuclear extracts from THP-1 monocytes we identified the ETS TF PU.1 to bind 
position G-578A with significantly higher affinity towards the G allele. Very interestingly, we 
were recently able to demonstrate an association of G-578A with cardiac resynchronisation 
therapy phenotype, in that the G allele was associated with response to cardiac 
resynchronisation therapy in patients with heart failure after MI (Schmitz, for FP7 VPH2). 
Computational analysis of the proximal region of the exact position identified a repeat of PU 
boxes of the 5'-GGA(A/T)-3' type, which is partly corrupted by introduction of the A allele. 
Multiple studies have demonstrated that PU.1 is essential for the development of 
hematopoietic cells of myeloid, B-cell, and T-cell lineages (Scott et al, 1994) and is further 
actively involved in regulation of genes in monocyte-derived macrophages (Nacu et al., 
2008). Despite its predominant expression and pivotal function in hematopoietic lineages, 
PU.1 is in addition expressed in fibroblasts, which are important structural elements of tissue 
integrity synthesizing ECM components, and has the potential to convert fibroblasts into  
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macrophage-like cells (Feng et al., 2007). PU.1 can directly bind to TFIID, mediated by the 
activation domain of PU.1, without the need for an adaptor protein as shown necessary for 
SP1 (Hagemeier et al., 1993). Since PU.1 is not expressed in endothelial cells such as the 
EA.hy926 linage, other members of the ETS family could potentially bind to the presented 
PU boxes.  
In fact, ETS proteins are described to play a major role in endothelial cells and all 
characterized endothelial enhancers contain multiple ETS binding sites (Bernat et al., 2006; 
De Val & Black, 2008). At least 19 different ETS proteins are expressed in human endothelial 
cells (Hollenhorst et al., 2004; Liu & Patient, 2008). ETS factors are critical for ECM 
remodeling (Trojanowska, 2000) and deletion of ETS genes leads to impairment of this 
process (Pham et al., 2007; Oettgen, 2006). Great redundancy is observed among the majority 
of ETS factors, which probably reflects their binding to identical cis-acting elements, the 
consensus motif highly conserved among all members of the family (De Val & Black, 2009). 
Notably, the exact consensus motif (the PU box) was initially identified to substitute for the 
deleted wt enhancer element of the SV40 promoter (Klemsz et al., 1990). In our study, we 
observed a significant enhancer activity of the G-578A region in the pGL3-Promoter context, 
too. Controversially and despite the observation that both alleles were able to enhance SV40 
promoter activity, total abrogation of promoter transcriptional activity was observed upon 
introduction of the A allele in the MolHap context cloned in pGL3-Basic vector. Indeed, it 
has been estimated that ETS proteins contribute to endothelial-specific gene expression, 
despite their overall ubiquitous expression in adult tissues and ETS binding sites being not 
specific to endothelial-expressed gene loci, by functioning in combination with other 
transcription factors. An interesting effect has been described concerning the interplay of ETS 
proteins and SP1. Trojanowska (Trojanowska, 2000) reported that two distinct ETS protein, 
FLI1 and ETS1, contribute to the regulation of the COL2A1 gene in fibroblasts. A functional 
PU box was identified in the COL2A1 promoter in close proximity to the SP1 sites. ETS1 and 
FLI1 had opposite effects on the activity of this promoter. While ETS1 stimulated 
transcriptional activity, FLI1 inhibited the promoter activity and SP1 binding was essential for 
this inhibitory effect of FLI1. It is conceivable that different ETS factors, like ETS1 and FLI1, 
are in active competition at position G-578A in EA.hy926 cells, as we have shown binding of 
the ETS family member PU.1 at this position in THP-1 cells. Binding affinity for PU.1 is 
altered in this cell line upon introduction of the A allele and a similar effect, leading to 
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augmented binding of an excessive TF, could contribute to the observed abrogation of 
transcriptional activity in EA.hy926 cells.  
 
5.5 Effect of TGF-β1 on BGN gene expression and TF binding 
 
The multifunctional cytokine TGF-β1 has been described to be a key regulator of ECM 
assembly and remodeling. TGF-β1 is well known to modify BGN at the posttranslational 
level (Little et al., 2008) by hyperelongation of chondroitin sulfate chains, leading to 
enhanced BGN binding affinity to LDL. However, inconsistent TGF-β1 effects on BGN gene 
expression have been reported. Ungefroren & Krull (Ungefroren & Krull, 1996) did not 
observe any effect on transcriptional activity of BGN promoter fragments, while Heegaard 
and colleagues (Heegaard et al., 2004) reported increased BGN mRNA levels as well as 
increased reporter gene activity. Here we report a significant enhancing effect of TGF-β1 on 
both, mRNA levels and promoter transcriptional activity. This effect was however limited to 
THP-1 monocytes, whereas no such effect was observed in EA.hy926 cells. Controverse 
findings from other groups could thus as well originate from different cell lines analysed. To 
reveal the mechanistic process of TGF-β1 signal transduction towards the BGN promoter, we 
used nuclear extracts derived from TGF-β1 treated cells in EMSA experiments and observed 
an altered DNA binding pattern at positions G-578A. Using SP1-specific antibodies we 
identified selective SP1 binding at this distal position in EA.hy926 and THP-1 cells after  
TGF-β1 stimulation, while no binding of SP1 was detected under basic  
conditions.  
Previously published reports have established a role for SP1 as the primary TF to be essential 
for the response to the TGF-β1 signal (Datto et al., 1995) and consequently, TGF-β1 
induction mediated by SP1 has been shown for several genes (Inagaki et al., 1994; Li et al., 
1998; Botella et al., 2001; Greenwel et al., 1997). Considering a simple linear effect of 
promoter activation by an increase in SP1 protein level, we assessed nuclear SP1 availability 
after TGF-β1 stimulation in comparison to basic conditions. We did not observe alterations in  
SP1 protein levels in neither cell line, but rather a slight tendency towards SP1 reduction in 
THP-1 cells. The observed effect might more likely be explained by enhanced SP1 binding to 
its consensus motifs. Recent reports have proposed a TGF-β1-activated SMAD2/3 
phosphorylation pathway, along with p38MAPkinase signalling, to be responsible for the 
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TGF-β1-mediated elongation of GAG chains on proteoglycans. Subsequently, inhibiting 
SMAD2/3 phosphorylation antagonized the GAG elongation effect (Dadlani et al., 2008). 
Overexpression of both SMAD2 and SMAD3 potentiated the TGF-β1 effect on BGN 
expression, whereas overexpression of SMAD7 impaired the effect, suggesting the 
participation of the entire SMAD signalling cascade in TGF-β1 regulation of BGN gene 
expression (Chen et al., 2002; Ungefroren et al., 2005). This mechanism relies on the physical 
interaction of SMAD with SP1 and results in enhanced binding of the TF to its consensus 
motifs. High expression levels of TF SP1 in EA.hy926 cells under basic conditions could 
provide an explanation for the continuously high BGN promoter activity and the absence of 
any TGF-β1 effect in the endothelial cell line. Selective phosphorylation and 
nucleocytoplasmic shuttling of SMAD in case of THP-1 cells expressing SP1 at low levels 
could account for an orchestrated response to TGF-β1 in monocytes. 
Characterizations of knock-out mice for TGF-β signalling components have furthermore 
demonstrated the critical role of SMAD proteins in vascular development and disease (ten 
Dijke & Arthur, 2007), with an essential function of SMAD3 in angiotensin II‑induced 
vascular fibrosis, characterized by arterial wall thickening through excessive deposition of 
ECM (Wang et al., 2006). The authors explicitly state that activation of SMAD3 but not 
SMAD2 is a key mechanism by which angiotensin II mediates arteriosclerosis. These 
observations might contribute to the positive association of SMAD3 with CAD (Samani et al., 
2007) in the Welcome Trust Case Control Consortium study (which involved 1926 case  
subjects with CAD and 2938 controls) and combined analysis in the German MI Family 
Study (which involved 875 case subjects with MI and 1644 controls). 
 
5.6 Conclusion 
 
The impact of genetic variants on molecular biologic function has been repeatedly 
demonstrated. A pars pro toto example is given by the listed co-authorships including in vitro 
functional analyses on human ICAM-1, VCAM-1 and osteoprotegerin. Genetic variants 
located in regulatory regions do not directly alter amino acid sequences or protein structure, 
but can initiate profound transcriptional (i.e. regulatory) consequences. Individual genetic 
predisposition strongly determines the clinical progression of arteriosclerosis and CV 
outcome alongside with environmental and lifestyle factors as shown originally by twin 
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studies (Marenberg et al., 1994). Most recent whole-genome approaches with large study 
cohorts using DNA micro array technologies have provided new insight into aetiology of 
CVD and related diseases, generating a heterogeneous set of candidate genes and associated 
loci (Vasan et al., 2009; Samani et al., 2007; MIGC, 2009; Ikram et al., 2009; Newton-Cheh 
et al., 2009). To some extend surprising in the first place, common base to most of the 
identified loci was their position in intergenic regions rather than within or near protein 
coding regions. Simultaneously, advances in deciphering of gene regulatory mechanisms have 
underlined the pivotal role of non-coding DNA regions, executing their function despite their 
distal position to the multiple genes they control (Heintzman & Ren, 2009). Additional 
aspects of association with non coding DNA regions may exist in small-RNA mediated 
pathways that have central roles in the silencing of gene expression in eukaryotic cells, with at 
least 30% of human genes thought to be regulated by microRNAs (Jinek & Doudna, 2009). 
With the newly identified genetic variants available, profiling the functional basis of disease 
association and generation of mechanistic insights becomes ever more important (Brand-
Herrmann, 2008). This includes not only analysis of single polymorphic positions towards 
their functionality but investigation of the entire structure of candidate gene promoters and 
interacting molecules with respect to pathophysiological conditions.  
As shown in the current work, the analysis of naturally occurring MolHap constellations 
within a defined cellular and genomic context is needed to identify the effects of single 
genetic variants on TFBS and regulation of gene expression. We provide substantial evidence 
that MolHaps affect the transcriptional regulation of the human BGN gene to a great extent. 
This is caused by alterations in TFBS at cis-regulatory elements and a subsequent change in 
TF binding affinities (as shown explicitly for PU.1 and the -578A allele). We further propose 
the regulation of BGN by TGF-β1 signal transduction and SMAD proteins to act, at least in 
part, through increased binding of TF SP1 to the polymorphic positions. Due to the dual role 
of BGN in arteriosclerosis pathophysiology, estimation of potential effects in patients 
carrying either BGN MolHap seems rather conjectural. However, the following arguments 
will have to be considered. Local BGN availability is essential for collagen deposition and 
formation of stable fibrous caps in aortic plaques as well as for remodeling processes after 
MI. Reduced BGN gene expression due to the presence of MolHap2 and 3 could violate these 
processes, resulting in more severe outcomes. Looking at the other side of the medal, with 
systemic and in situ inflammatory processes influencing arteriosclerosis to a great extend, 
proinflammatory proteins such as BGN may execute their negative effects on disease 
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progression or early onset. BGN MolHap2 and 3 could therefore also account for protective 
effects, reducing BGN gene expression and the inflammatory burden. 
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6 PERSPECTIVE 
 
The genetic predisposition for multifactorial and complex diseases such as CAD has become 
common knowledge. Large twin studies of the past 25 years provided comprehensive data 
numbering the genetic impact on disease susceptibility to at least 50%. Despite a rising 
number of proposed and analysed candidate genes, the multilayer and interlaced 
pathophysiology combined with different stages of the disease has circumvented explicit 
explanations of its development, progression and severity. GWA studies using large 
prospective and retrospective cohorts have provided large amounts of data widening the 
insight into the disease complexity even more, identifying significant associations of genetic 
variants with progression and severity of CAD. However, the molecular mechanisms of the 
identified variants are not well understood, impeding their use for therapeutic target 
identification or even risk prediction. It is obvious that understanding the functionality of 
human gene regulation and the impact of the interpersonal variable genome structure, 
especially in promoter regions, is mandatory. Since we have only started to understand the 
variable structure of the genome and its alterations throughout an individual’s life span by 
epigenetic processes, this task seems unobtainable with currently available resources.  
Molecular functional characterization of genetic variants, as presented exemplarily in this 
work, may contribute to our understanding of gene regulation by cis-active elements and 
trans-acting factors. The concept of individual MolHaps thereby is a next step accounting for 
an individual genome. Future work will have to account for the interaction within relevant 
pathophysiological pathways, considering the impact of genetic variants on cell-specific gene 
regulation. Identified functional variants within candidate genes are meanwhile integrated in 
latest approaches towards disease modelling (e.g. the VPH2 project), using data mining 
modules to identify combinations of genetic variants for risk prediction and identification of 
yet unknown underlying pathways and mechanisms. 
The field of structural biology has so far provided three-dimensional (3D) structures of more 
than 45000 proteins. High-throughput methods for solving protein 3D structures are currently 
under development. Protein sequences can be predicted from their coding DNA and structural 
information can be used to predict the preferred substrate of a protein, identifying potentially 
recognized DNA sequences. Variations in the coding region of a gene can thus be translated  
into altered amino acid sequences and altered DNA binding capacity and kinetics. Most 
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promising technological advances thereby come from the field of NMR spectroscopy, 
decreasing size limitations and providing greater accuracy. As a result, information has 
become available on the way in which proteins interact with other biomolecules such as 
DNA. Coupling these advances with the exponential increase in data processing and storage 
could open the door for life imaging of gene regulation processes. 
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